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1 Introduction 
1.1 Vaccination  
The most efficacious and cost-effective possibility to interfere with infectious diseases 
is the prophylactic immunization against pathogens. Therefore, the development of 
new or improved vaccines is one of the most important challenges in modern 
medicine to prevent human morbidity and mortality caused by different infectious 
microorganisms. 
The early concept of vaccination is based on the observation by Edward Jenner in 
1796 that prior exposure to cowpox (vaccinia) could protect against subsequent 
challenge with virulent smallpox (Jenner, 1798). Pasteur, who developed over 
hundred years later a vaccine against chicken cholera (Pasteur, 1880), extended the 
term vaccination to the stimulation of protection to other infectious agents 
(Silverstein, 1998). 
The development and widespread use of vaccines against a variety of pathogens has 
been a great triumph of medical science, and many major diseases, such as 
diphtheria, poliomyelitis and measles are kept under control in industrialized 
countries. In the case of smallpox, it even resulted in a worldwide eradication of the 
pathogen. 
Despite this outstanding success, vaccines for many diseases throughout the world, 
like AIDS caused by the human immunodeficiency virus (HIV), tuberculosis caused 
by Mycobacterium tuberculosis, leishmaniasis caused by Leishmania major and 
malaria caused by Plasmodium falciparum are either not available or ineffective. 
Therefore, there is a growing need for the development of completely new vaccines, 
besides improvement of existing vaccines in terms of efficacy and safety. 
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1.1.1 Requirements for an effective vaccine 
According to the nature of the infecting organism, the particular requirements for 
successful vaccination can vary extremely. Whereas humoral responses, mediated 
by antibodies, can directly attack microorganisms and subsequently prevent 
infection, T cells as instruments of cellular immune responses work by killing infected 
cells. Thus, T cells cannot prevent infection; rather they contribute to host defense 
and clearance of pathogens (Srivastava and Liu, 2003). The ideal vaccine therefore 
provides host defense already at the point of entry of the pathogen. Consequently, 
the stimulation of mucosal immunity plays an important role in vaccination, since 
most infectious organisms enter the host through mucosal surfaces.  
Immunity against most viral and bacterial infections is mediated by a humoral 
immune response (production of antibodies). Some microorganisms such as the 
causative agents of tetanus and diphtheria, Clostridium tetani and Corynebacterium 
diphtheria, respectively, as well as the intracellular poliomyelitis virus require the 
presence of preexisting neutralizing antibodies for an effective protective immunity 
(Makela, 2000). For intracellular infectious microorganisms such as Mycobacterium 
tuberculosis, Leishmania major, and other parasites, protection is mediated by 
cellular immunity. Moreover, for some diseases (e.g. HIV infection, herpes and 
malaria), both humoral and cellular responses are likely to be required. The cellular 
immune responses comprise primarily CD4+ and CD8+ T cells in these cases 
(Gurunathan et al., 2000). This demonstrates the versatility of problems that need to 
be tackled in vaccine design. 
In addition, one very important criterion for a successful vaccine is its ability to 
produce protective immunity against exposure to live pathogens in a very high 
proportion of the population. Such a vaccine should generate long-lived 
immunological B as well as T cell memory to give sustained protection already after a 
single application, as it is impractical to administer booster vaccinations to large or 
dispersed rural populations. Furthermore, the vaccine should be safe. Since vaccines 
must be given millions of people all over the world, including young and elderly as 
well as immunocompromised, they must not cause itself illness or even death by the 
disease it is designed to prevent.  
Another criterion is that vaccines must be very cost effective, if they are to be applied 
to large populations especially in developing countries. They should be easy to 
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handle e.g. avoiding a cold chain and trained personnel for administration. 
Furthermore, no or only few side effects should be provoked by vaccination (Ada, 
1990). 
1.1.2 History of vaccine development 
Following the success of Jenner´s and Pasteur´s vaccines against smallpox (Jenner, 
1798) and chicken cholera (Pasteur, 1880) or rather rabies (Pasteur, 1885), vaccine 
development in the early part of the 20th century took two different pathways. On the 
one hand, vaccinations were performed by the use of attenuated organisms with 
reduced pathogenicity but still able to stimulate protective immunity. However, any 
live vaccine can cause lethal systemic infections in the immunosuppressed and e.g. 
for measles and polio widespread use is prevented in developing countries due to 
technical and economical problems. On the other hand, vaccines based on killed 
inactivated organisms were tested. Killed whole-cell vaccines cannot replicate and 
are therefore non-infectious. But they are also less immunogenic than live vaccines 
and often require booster injections and additional adjuvant. 
During the second half of the 20th century, detailed molecular understanding of 
microbial pathogenicity and protective host response towards pathogens has arisen. 
Together with the knowledge about the regulation of the immune system to generate 
effective T- and B-lymphocyte responses, a more rational approach of vaccine 
design was developed leading to enhanced effectiveness of vaccines that will finally 
fulfill the criteria of an optimal vaccine (Makela, 2000). 
Classical subunit vaccines 
Knowledge of the nature of individual antigens or the immune response they elicit 
and rapid advances in molecular biology have led to the development of subunit 
vaccines based on purified components of pathogens such as bacterial poly-
saccharides, viral surface proteins or detoxified toxins that were as effective as live 
whole vaccines (e.g. pertussis toxin). Pure subunits of pathogenic origin are safer to 
use as vaccines than live organisms, but are often very sumptuous and risky in their 
production due to the large-scale cultivation of pathogenic organisms. In addition, this 
type of non-recombinant subunit vaccines often needs coadministration of adjuvants 
or conjugation to protein carrier to render them more immunogenic (Liljeqvist and 
Stahl, 1999). 
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As example, many bacteria, including Streptococcus pneumonia and Haemophilus 
species, have an outer capsule composed of polysaccharides that are species- and 
type-specific for particular strains of the bacterium. The most effective defense 
against these pathogens is opsonization of the polysaccharide coat with antibodies. 
However, capsular polysaccharides elicit only a T-cell independent antibody 
response and are therefore not suitable in young children under the age of 2 years. 
To overcome this problem, bacterial polysaccharides are chemically conjugated to 
protein carriers, which provide peptides that can be recognized by antigen specific T 
cells, and converts the antibody response against the polysaccharide into a T-cell 
dependent response. Various conjugate vaccines have been developed against 
Haemophilus influenzae and are nowadays in use (Peltola et al., 1992; Rosenstein 
and Perkins, 2000). 
Usually, purified antigens are not immunogenic on their own and therefore require 
the presence of adjuvants (e.g. alum, pertussis toxin) to improve the immunogenicity 
of vaccines. Adjuvants are defined as substances that enhance the immunogenicity 
of antigens (Ramon, 1924) by their ability to directly activate an immune response or 
to act as delivery system (Pizza et al., 2002). Many adjuvants provide “danger 
signals” and activate cells of the innate immune system, which in turn activate 
immune responses by secreting a wide-range of inflammatory mediators and 
cytokines (Medzhitov and Janeway, Jr., 1998; Aderem and Ulevitch, 2000). For 
example, tetanus toxoids often contain aluminum salts, which bind polyvalently to the 
toxoids by ionic interactions and then selectively stimulate antibody responses. In 
contrast, pertussis toxin has its own adjuvant properties and, when given mixed as a 
toxoid with tetanus and diphtheria toxoids as so called DPT triple vaccine, not only 
vaccinates against whooping cough but also acts as an adjuvant for the other two 
toxoids. In addition, adjuvants like aluminum phosphate act by depot formation at the 
injection site that permits a slow release of antigen. Thus, the duration of interaction 
between antigen and antigen-presenting cells and lymphocytes is prolonged (Glenny 
et al., 1931; Gupta, 1998). 
Adjuvants can also modulate immune responses and facilitate the induction of 
cytotoxic T lymphocyte (CTL) responses against coadministered antigens. Different 
adjuvants may promote different types of response, for example, an inflammatory T 
helper 1 (Th1) response or an antibody-dominated Th2 response. Some adjuvants, 
like pertussis toxin, stimulate mucosal immune responses. 
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Moreover, coadministration of cytokines can enhance and modulate the immune 
response into the desired direction. For instance, coadministration of Interleukin-12 
(IL-12) with a vaccine containing leishmania antigens abrogate the predominantly 
Th2 response in susceptible mice and generate a Th1 response leading to protection 
against Leishmania major (Scott and Trinchieri, 1997). 
Recombinant subunit vaccines 
Through identification of relevant protective antigens and advances in molecular 
biology, subunit vaccines could be established recombinantly by isolating the coding 
gene and transferring it to a non-pathogenic organism. The recombinant antigen is 
then produced by the heterologous host, thus excluding the pathogen itself, which 
eliminates risks associated with the production, as well as risks for contamination 
with toxic compounds. Furthermore, the antigen can be modified regarding optimized 
production of recombinant protein (high yield, easy purification, minimal proteolysis) 
and enhanced immunogenicity (e.g. use of fusion proteins). This resulted in the first 
recombinant subunit vaccine, the Hepatitis B surface antigen vaccine, produced in 
Saccharomyces cerevisiae (Valenzuela et al., 1982) that was licensed in 1986 
(reviewed by Liljeqvist and Stahl, 1999). 
Peptide vaccines 
Chemically synthesized peptides of protective T cell epitopes against infectious 
diseases can elicit a strong immune response when delivered together with a carrier 
(Simard et al., 1997) or an adjuvant (Hsu et al., 1996). For example, immunogenical 
peptides can be genetically integrated into carrier proteins within a viral vector, such 
as hepatitis B core antigen, which are then processed in vivo through natural antigen-
processing pathways. In contrast, ISCOMs (immune stimulatory complexes), which 
are lipid carriers that act as adjuvants with minimal toxicity, encourage the entry of 
peptides into the cytoplasm, thus enhancing the loading of peptides onto major 
histocompatibility complex (MHC) class I molecules (Cox et al., 1998). Synthetic 
peptide vaccines could be chosen to stimulate predominantly either the humoral or 
cellular branch of the immune response. However, a single epitope-based vaccine is 
not likely to be effective in an out-bred population like humans since the cellular 
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response will be restricted to a particular human leukocyte antigen (HLA), which will 
be present only in some individuals of the population. 
Attenuated pathogens 
Most antiviral vaccines presently in use consist of inactivated or live attenuated 
viruses. Thus, against polio, measles, mumps, rubella and varicella attenuated viral 
vaccines are used. Live attenuated viral vaccines have the advantage that they are 
generally more potent in eliciting relevant effector mechanisms, including cytotoxic 
CD8+ T cells, in contrast to inactivated viruses. On the other hand, they bear the risk 
of reverting to the virulent form. Although today, attenuation can be achieved more 
reliable by employing recombinant DNA techniques, minimizing the risk of reversion 
of the vaccine virus to a virulent strain, attenuated viral vaccines can nevertheless 
pose particular risks to immunodeficient recipients in whom they often behave as 
virulent opportunistic infections. 
In contrast, most bacterial vaccines nowadays, like tetanus, diphtheria and whooping 
cough (caused by Bordetella pertussis), consist of inactivated toxins or toxoids of the 
corresponding bacteria. This is however limited to bacteria with toxins that are 
responsible for pathological conditions. Therefore, strategies to engineer genetically 
defined attenuations for pathogenic bacteria are also used for vaccine development 
(e.g. Salmonella typhi) (Levine et al., 2002).  
Routes of vaccination 
Nowadays, most vaccines are given parenteral by injection. Nevertheless, this kind of 
immunization suffers from several disadvantages. First, injections are expensive due 
to the requirement of sterile needles and syringes as well as trained personnel. They 
are therefore not well suited for mass vaccination in developing countries. Second, 
parenteral administration may not be the most effective way of stimulating an 
appropriate immune response at the mucosa. Most pathogens like B. pertussis, 
influenza virus, Vibrio cholerae, S. typhi, E. coli and Shigella usually enter the host 
through mucosal surfaces and immunity at this site is required for protection. 
Therefore, efforts are undertaken to develop vaccines that can be administered via 
the mucosa orally or by nasal inhalation. In this respect, the use of live attenuated 
bacteria or viruses has been investigated for the induction of local mucosal as well as 
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systemic immune responses. For example, the live-attenuated polio vaccine (Sabin) 
consisting of three attenuated polio virus strains is highly immunogenic and effective 
by the oral route (Minor, 1992). 
Vaccine carriers 
By means of engineering genetically defined attenuated strains of bacteria and 
viruses which are non-pathogenic, such live vaccines are not only valuable in their 
own right but could also serve as vectors for the delivery of antigens from other 
pathogenic organisms. In the mouse, infection with Salmonella stimulates a powerful 
mucosal and systemic immune response and, in addition, can be used as carrier to 
stimulate the mucosal immune system against heterologous antigens. Attenuated 
strains of Salmonella have already been used successfully as carriers of 
heterologous antigens from organisms like Listeria monocytogenes (Hess et al., 
1996), Bacillus anthracis, L. major (Aggarwal et al., 1990; McSorley et al., 1997), 
Yersinia pestis and Schistosoma mansoni (Khan et al., 1994) resulting in protection 
of mice against an experimental challenge with the respective pathogen. 
Similarly, viral vectors like vaccinia (Mackett et al., 1982; McMahon-Pratt et al., 1993; 
Katz and Moss, 1997) or adenovirus (Fooks et al., 1995; Xiang et al., 1996; Mittal et 
al., 1996) can be engineered to carry heterologous peptides or proteins and can be 
used as single or combined vaccine against several different organisms. However, 
this type of a viral vaccine can only be used once, since long-lasting immunity is 
generated against the carrier that will neutralize its effectiveness upon a second 
administration. Prime-boost immunization strategies are therefore developed that, for 
instance, use DNA vaccines (see below) to prime and recombinant viral vectors as a 
booster. Improve of immunity against HIV in a primate model (Letvin et al., 1997; 
Robinson et al., 1999; Fuller et al., 1997), malaria (Sedegah et al., 1998) and HSV 
(Eo et al., 2001) was elicited this way. 
Novel experimental approaches 
In novel approaches, plant viruses, which are non-pathogenic in humans, were 
employed as vaccine vectors. Such viruses can be engineered to incorporate 
heterologous antigens into transgenic plants for direct mucosal delivery as food (Haq 
et al., 1995; Tacket et al., 1998; Arakawa et al., 1998). 
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An unexpected highly versatile new vaccination strategy was discovered recently. 
(Wolff et al., 1990; Tang et al., 1992). Isolated plasmid DNA encoding a foreign 
protein under the control of a suitable promoter was injected directly into muscle or 
skin by syringe or applied as DNA coated gold beads by gene gun. Uptake of the 
DNA by cells of the host causes expression of the plasmid encoded protein (Williams 
et al., 1991; Wolff et al., 1990). This has been shown to engender both cellular and 
humoral immune responses in a variety of rodent and primate disease models 
(reviewed by Donnelly et al., 1997). Recently, several DNA vaccines have entered 
human clinical trials for various diseases, including influenza, hepatitis B, HIV, 
malaria as well as cancer (reviewed by Srivastava and Liu, 2003). The predominant 
ability of DNA vaccines to generate cellular immune responses may be crucial for the 
design of completely novel and/or more effective vaccines against intracellular 
organisms that only can be fought by cell-mediated immunity such as Mycobacterium 
tuberculosis, Plasmodium falciparum, Leishmania and HIV. In contrast, currently 
available vaccines against most viruses and bacteria are based on the induction of a 
long-lived humoral antibody production against the pathogen. 
As extension, the use of bacteria as delivery system for antigen-encoding plasmid 
DNA has recently been shown to provide a highly efficient alternative to 
intramuscular or intradermal immunization of DNA. Using bacteria for oral delivery of 
DNA vaccines combines the advantages of the adjuvant properties of bacterial 
vectors, the selectivity to target antigen-presenting cells and immune-inductive sites, 
with the versatility of DNA vaccines. Thus, it stimulates efficiently humoral, T helper 
and cytotoxic responses, systemically as well as mucosally. Extremely promising 
results have been already obtained using attenuated Salmonella strains (Darji et al., 
1997, 2000; Weiss, 2003) or invasive intracellular pathogens such as Shigella spp. 
(Sizemore et al., 1995). 
1.2 DNA vaccination 
The use of DNA plasmids to induce immune responses by direct injection of DNA 
that encode antigenic proteins has been termed DNA vaccination or genetic 
immunization (Wolff et al., 1990; Tang et al., 1992). DNA vaccines employ genes 
encoding proteins of pathogens, rather than the protein or an attenuated version of 
the pathogen itself. Since the 1990s it has been shown that this method elicits cell-
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mediated immune responses and protective antibodies in a number of animal models 
for viral, bacterial and parasitic diseases (Donnelly et al., 1997), but has also been 
effective in tumor models and to ameliorate allergic reactions (reviewed by 
Gurunathan et al., 2000). 
DNA vaccines generally consist of a bacterial plasmid with an origin of replication 
(e.g. pUCori) suitable for high yields of plasmid and an antibiotic resistance gene to 
confer antibiotic-selected growth in E. coli. In addition, the plasmid includes a strong 
viral promoter (e.g. human cytomegalovirus immediate/early promoter (Boshart et al., 
1985)), the gene of interest and an mRNA transcript termination/polyadenylation 
sequence (e.g. from SV40 (Pfarr et al., 1986)) for directing expression in mammalian 
cells (Williams et al., 1991; Wolff et al., 1990). The plasmid is grown in bacteria  
(E. coli), purified, dissolved in saline solution and then injected into the host. 
Upon injection, protective antigen from the particular pathogen is expressed. After 
processing of this endogenous antigen, presentation of antigenic peptides bound to 
MHC class I molecules then initiate activation of cytolytic T cells (Ulmer et al., 1993). 
In addition, T helper cells and B cells are stimulated, which consequently results in 
protection to a challenge with pathogenic microorganisms and tumors (Xiang et al., 
1994; Sedegah et al., 1994). How these immune responses are generated, still 
remains unclear. Due to the relative small amounts of proteins synthesized during 
DNA vaccination, the most likely explanation for the efficient induction of a broad and 
sustained immune response is the immune-enhancing properties of the DNA itself 
and/or the type of antigen presenting cells (APC) transfected. There are at least three 
mechanisms by which antigens encoded by plasmid DNA could be processed and 
presented to the immune system: a) direct priming by somatic cells (e.g. myocytes, 
keratinocytes); b) direct transfection of professional APCs (e.g. dendritic cells (DCs)); 
and c) cross-presentation. 
In several studies, it was demonstrated that bone marrow-derived APCs, rather than 
myocytes or keratinocytes, mediate cellular immune responses (including CD4+ and 
CD8+ T cells) after DNA vaccination (Corr et al., 1996; Doe et al., 1996; Iwasaki et 
al., 1997; Torres et al., 1997). Moreover, injection into muscle (Porgador et al., 1998; 
Akbari et al., 1999) as well as gene gun vaccination into skin (Condon et al., 1996) 
leads to direct transfection of DCs that can present antigen efficiently to T cells. 
Somatic cells apparently express only low amounts of MHC class I molecules, but 
neither MHC class II (Hohlfeld et al., 1991) nor costimulatory molecules such as B7.1 
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or B7.2. Therefore, they need to transfer the antigen encoded by the DNA vaccine to 
professional APCs by a process called cross-presentation, in order to induce T cells 
(Fu et al., 1997). Until now, this mechanism has been only partly elucidated. During 
cross-presentation secreted proteins or peptides from somatic cells and/or 
professional APCs can be taken up by neighboring DCs via phagocytosis of either 
apoptotic or necrotic bodies. In turn, the exogenous antigens were directly 
transferred to the cytosol and can be presented to T cells in the context of MHC  
class I as well as MHC class II. Processing of antigens via MHC class I and MHC 
class II pathways could directly stimulate naïve CD8+ T cells and CD4+ T cells, 
respectively (Heath and Carbone, 2001). Although the immune response elicited by 
genetic immunization is weak compared to that induced by traditional vaccines, it is 
exceptionally long lasting (Davis et al., 1994; Xiang et al., 1994). 
Genetic vaccination offers several advantages over traditional vaccines and potential 
solutions for current problems in vaccination: 
- A major attribute of DNA vaccines is their ability to deliver genes into cells for 
generation of MHC class I restricted cytolytic T lymphocyte responses. Ulmer 
could demonstrate that DNA vaccination against influenza provides broader 
protection against different strains of the virus (Ulmer et al., 1993). This was 
due to the generation of cytotoxic T lymphocytes that recognized epitopes 
from conserved proteins inside the virus capsid or proteins that are only 
expressed during the infection cycle. In contrast, antibodies are normally 
directed against surface or envelope proteins. 
- The outstanding feature of DNA vaccines to induce MHC class I-restricted 
cytotoxic T lymphocytes (CTLs) against entire proteins (rather than peptides) 
allows determinant selection to occur in the host. Thereby, DNA vaccines are 
efficacious across the diversity of the MHC haplotypes, as has been already 
shown in mice immunized with nucleoprotein from influenza A virus (Ulmer et 
al., 1993), hepatitis B surface and core protein (Schirmbeck et al., 1995; 
Kuhrober et al., 1997), and HIV env and gag antigens (Shiver et al., 1995, 
1997; Liu et al., 1996; Boyer et al., 1998; Thomson et al., 1998). 
- Induction of antigen specific cytolytic T cell responses by DNA vaccination has 
likewise been observed in non-human primates ( Donnelly et al., 1995; Liu et 
al., 1996; Amara et al., 2001; Barouch et al., 2001) and in human clinical trials 
(Wang et al., 1998). Thus, it demonstrates its efficacy in outbred populations. 
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Moreover, cellular responses elicited upon genetic immunization were 
demonstrated to be protective in models of influenza virus (Ulmer et al., 1993), 
lymphocytic choriomeningitis virus (Yokoyama et al., 1995; Martins et al., 
1995), and herpes simplex virus (Manickan et al., 1995; reviewed by 
Srivastava and Liu, 2003). Accordingly, DNA vaccines offer a simple 
alternative to conventional methods to generate CTLs, such as immunization 
with peptides or live attenuated viruses. 
- Expressing the endogenous synthesized antigen with native posttranslational 
modifications (e.g. glycosylation pattern), conformation, and oligomerization to 
elicit antibodies of optimal specificity (particular advantageous for viral 
proteins) have contributed to protection in preclinical disease models against 
challenge with the relevant infectious pathogen like influenza (Ulmer et al., 
1993, 1994), rabies virus (Xiang et al., 1994) hepatitis B virus (Prince, 1996), 
M. tuberculosis (Huygen et al., 1996; Tascon et al., 1996)or L. major (Xu and 
Liew, 1995). In addition, DNA vaccines stimulate helper T cell responses 
which contribute to the long-lasting immune response (Donnelly et al., 1997). 
- Vectors for genetic immunization are easily to construct and the genes 
inserted into a plasmid can be modified readily, allowing removal or insertion 
of transmembrane domains, signal sequences or residues effective in protein 
processing. 
- Certain sequence motifs, such as CpG motifs, in bacterial plasmid DNA can 
function itself as adjuvant or immunomodulator (Krieg et al., 1995a; Sato et al., 
1996). 
- Altering the nucleotide sequence of the vector may affect the immunogenicity 
of DNA vaccines (Yamamoto et al., 1992; Krieg et al., 1995a; Sato et al., 
1996).  
- The stability of genetic vaccines as well as their heat resistance eliminates the 
need for a cold chain, which is very important for the use in developing 
countries. 
- The DNA can be detected during a long period of time, indicating that it acts 
as antigen depot (Zhu et al., 1993). Thereby, genetic vaccines induce long-
term memory for T and B cells and can provide upon a single inoculation long-
lasting protective immunity (Ertl and Xiang, 1996). 
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- DNA vaccines do not carry any risk of converting to virulence (Ertl and Xiang, 
1996). 
- The plasmids are constituted without an origin of replication that is functional 
in eukaryotic cells. Such plasmids neither replicate in the mammalian host nor 
should they integrate into the chromosomal DNA of the animal (Donnelly et al., 
1997).  
- The co-expression of cytokines or costimulatory molecules can enhance the 
immune response and offers the possibility of modulating the induction of an 
immune response into the desired direction (Xiang and Ertl, 1995; Geissler et 
al., 1997; Kim et al., 1997).  
- DNA vaccines, given intramuscularly and formulated in saline, elicit a Th1-like 
helper T cell response, whereas intradermal vaccination using a gene gun 
appears to bias the immune response towards Th2-like responses (Williams et 
al., 1991; Tang et al., 1992; Feltquate et al., 1997). In addition, the quantity of 
the plasmid DNA administered and the method and site of its introduction may 
significantly influence the types of immune responses generated against the 
proteins encoded by the plasmid. 
- The combination of diverse immunogens into a single preparation facilitates 
simultaneous immunization for several diseases.  
 
As already mentioned, the induced immune response is comparably weak. Thus, the 
DNA has to be inoculated several times and possibly with additional adjuvants. On 
the other hand, DNA vaccines are very effective in preclinical animal models, 
demonstrating the robustness of the technology. Nevertheless, there may be a need 
for improved formulations of DNA vaccines in human clinical trials that can lower the 
dose of DNA required for efficacy, that are more stable, or that transfect a greater 
number of cells or deliver a greater amount of DNA into cells.  
To account for these problems, prime-boost protocols have been developed (as 
mentioned above). In addition, targeting of certain tissues or cells for transfection by 
DNA vaccines may be desirable, particularly for cellular and mucosal responses 
(Ulmer et al., 1996). In this respect, the discovery to orally deliver plasmid DNA with 
attenuated enteric bacteria such as Salmonella, Shigella and Listeria has raised 
great interest and provoked extensive research activities. 
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1.3 Bacteria as live antigen delivery systems 
Since most pathogens usually enter the host through mucosal surfaces, the 
traditional way of injecting vaccines with needles may be not the most effective way 
to stimulate an appropriate immune response. Therefore, new vaccines that could be 
administered to the mucosa orally or by nasal inhalation are now designed. In 
addition, they should be delivered efficiently and selectively to antigen-presenting 
cells as well as modified for targeting them particularly into antigen-processing 
pathways within the cell.  
An understanding of mechanisms of mucosal immunity has led to the development of 
techniques to target antigens to microfold (M) cells that overlay Peyer´s patches.  
- M cell targeting with nonliving vaccines has proved difficult because 
unprotected macromolecules are readily digested in the intestine. 
Consequently, one approach has been to package antigens in microparticels 
that provide protection from intestinal enzymes and to take advantage of the 
fact that M cells can endocytose particles up to several µm in size (Eldridge et 
al., 1991). However, many of such microparticles, including liposomes, which 
also have been tested in this context, adhere to mucosal surfaces by 
hydrophobic interactions, but uptake by M cells is inefficient. 
- Macromolecules or particles can be conjugated or coated with ligands, such 
as CTB (cholera toxin subunit B), that allow passage through mucous gels and 
adherence to M cells. Nevertheless, accessibility to membrane receptors is a 
limiting factor (Frey et al., 1996). 
- ISCOMs consisting of cholesterol, phospholipids, cell membrane antigens and 
saponins (Cox et al., 1998) together with the immunogen has been 
demonstrated to induce cellular and humoral responses as well as local 
antibody responses after either intranasal or oral administration (Morein and 
Bengtsson, 1998; Mowat et al., 1999; Smith et al., 1998). 
- Oral application of DNA encapsulated into cochleates was shown to induce 
strong CTL and antibody responses (Mannino et al., 1998). Cochleates are 
rigid calcium-induced spiral bilayers of anionic phospholipids with a unique 
structure that are relatively stable after lyophilization or in harsh environments. 
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Despite of such promising approaches, mucosal delivery via inert carriers misses the 
efficiency required for a generally applicable vaccine. Exploiting pathogens that can 
target themselves to M cells and enter the mucosa at immune inductive sites can 
bypass these difficulties. Thus, invasive intracellular bacteria have been recognized, 
besides being carriers of heterologous antigens, to be efficient vehicles for the 
mucosal delivery of genes encoding protective antigens. Several advantages are 
associated with their use: 
- Attenuated live bacterial vaccines could prove considerably less expensive 
than killed preparations. Further, they are relatively economical in their 
manufacture and easy to conserve compared to tissue culture based, 
conjugated and purified subunit vaccines.  
- The employment of live attenuated bacteria as mucosal (oral or intranasal) 
rather than parenteral vaccine simplifies the administration (e.g. the use of 
sterile syringes is not required), which could avoid needle-stick transmission of 
pathogens (e.g. HIV), mainly in developing countries.  
- They could be expected to cause fewer side effects than traditional whole-cell 
enteric vaccines (e.g. killed typhoid vaccine) and the possibility to administer 
live vaccines as enteric capsules containing lyophilized organisms should 
ideally eliminate the need for a cold chain.  
- In contrast to oral subunit vaccines, that need coadministration of adjuvants 
like the cholera toxin of V. cholerae, the heat-labile enterotoxin from E. coli 
(LTB) or aluminum salts to induce efficacious immune response, live 
replicating bacterial vectors produce their own immunomodulating factors (e.g. 
cell wall components) in situ.  
 
As in the case of a natural infection with wild type organisms, mucosal immunization 
e.g. with attenuated Salmonella and Shigella stimulates every arm of the immune 
system. Consequently, attenuated Salmonella and Shigella constitute highly versatile 
live carriers for delivering heterologous antigens to the immune system. Such antigen 
could be expressed by the bacteria themselves by means of an open reading frame 
encoded by a prokaryotic expression plasmid or chromosomally integrated. 
Alternatively, eukaryotic expression plasmids (i.e. DNA vaccines) can be employed 
that are delivered to antigen-presenting cells for gene expression and immune 
stimulation. 
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1.3.1 Attenuated live bacteria as combined vaccines 
Both Gram-negative and Gram-positive bacteria, including mycobacterial strains 
have been investigated for delivery of foreign antigens. The particular antigen-
encoding DNA fragment can be inserted into the attenuated carrier by recombinant 
DNA techniques, either for chromosomal expression or introduced as prokaryotic 
expression system on a plasmid. Such live bacterial carriers have been extensively 
studied as mucosal vaccines, both against the corresponding disease caused by the 
wild type strain of the particular carrier as well as delivery system against diseases 
provoked by other pathogens. This vaccination strategy is based on the fact that the 
attenuated bacteria establish a limited infection, resembling early stages of infections 
generated by its wild type counterpart. This leads to the induction of natural immune 
reactions in the host to the carrier itself as well as their cargo. 
Live recombinant Gram-negative bacteria such as Salmonella enterica spp. (Sadoff 
et al., 1988; Clements et al., 1986; Tacket et al., 1990, 2000), Shigella flexneri (Ryd 
et al., 1992; Klee et al., 1997), Vibrio cholerae (Schodel et al., 1991; Acheson et al., 
1996; Lang and Korhonen, 1997), Yersinia enterocolitica (Sory and Cornelis, 1990), 
and Bordetella pertussis (Mielcarek et al., 1998) have been studied in animal models 
and human clinical trials as potential vaccine delivery systems for heterologous 
antigens. So far, Salmonella spp. and S. flexneri have been employed systematically 
as carriers. 
Genes encoding enzymes for production of polysaccharide antigens as well as 
protein antigens from various genera of bacteria, viruses and even eukaryotic 
parasites have been expressed in attenuated strains of Salmonella spp. either on 
plasmids or by genes integrated into the chromosome. Following mucosal 
immunization with these live vectors, specific serum IgG antibodies, secretory IgA 
(sIgA) mucosal antibody or cell-mediated immune responses were stimulated and 
conferred protection against a challenge with wild type organisms or toxins (reviewed 
by Levine et al., 2002).  
Although this Salmonella system is versatile, it has limitations. For example, 
Salmonella cannot glycosylate proteins. If glycosylation as post-translational 
modification of protective epitopes within viral proteins is required for correct folding 
of the antigen to stimulate specific antibodies against conformational epitopes, 
Salmonella can not be the vector system of choice (Levine et al., 2002). 
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1.3.2 Attenuated live bacteria for the delivery of DNA vaccines 
In the last few years, it has been demonstrated that attenuated intracellular bacteria 
can be used also as vehicle to efficiently target DNA vaccines to professional antigen 
presenting cells such as macrophages and DCs in vitro as well as in vivo.  
The concept of transkingdom transfer of eukaryotic expression plasmids between 
bacteria and mammalian cells has been first described by Schaffner (1980) several 
years ago, which was improved by the fusion between eukaryotic cells and 
protoplasts of plasmid carrying E. coli. By now, DNA-transfer between, Gram-
negative and Gram-positive bacteria (Trieu-Cuot et al., 1993; Charpentier et al., 
1999), between bacteria and yeast (Heinemann and Sprague, Jr., 1989), as well as 
bacteria and plants (Lessl and Lanka, 1994) is well established. More recently, 
transfer of DNA vaccines from viable bacteria to mammalian host cells has been 
discovered by four groups independently using attenuated strains of Shigella flexneri, 
invasive E. coli or Salmonella typhimurium (Sizemore et al., 1995; Darji et al., 1997; 
Courvalin et al., 1995; Powell et al., 1996). In the meantime, the number of bacteria 
that are able to transfer expression plasmids to mammalian cells in vitro and in vivo 
has been multiplied. The Gram-negative species S. typhi, S. choleraesuis, Yersinia 
pseudotuberculosis, Y. enterocolitica and the Gram-positive strain L. monocytogenes 
were successfully applied (Weiskirch and Paterson, 1997; Shiau et al., 2001; Dietrich 
et al., 1998, 2001; Hense et al., 2001; Al Mariri et al., 2002). 
Most intracellular bacteria can be transformed easily with DNA vaccine vectors. 
Accordingly, attenuated mutants still equipped with adhesion and invasion properties, 
can carry these plasmids selectively into the phagosome (Salmonella, invasive  
E. coli) or cytosol (Shigella, Listeria) of APCs, where they undergo lysis due to their 
metabolic attenuation, an inducible autolytic mechanism or treatment with 
appropriate antibiotics. Upon liberation of the eukaryotic expression plasmid due to 
lysis and translocation into the nucleus of the host cell, the encoded antigen is 
expressed and can subsequently induce humoral and cellular immune responses 
against bacterial, viral and tumor antigens conferring protection against bacterial and 
viral infection and tumor challenge (Weiss and Krusch, 2001; Weiss and 
Chakroborty, 2001). Mucosal application either nasally or orally of such recombinant 
bacteria additionally leads to transfection of the gut-associated lymphoid tissue, 
which induces efficient mucosal responses. This type of immunization was more 
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efficacious than either direct application of antigen, vaccination with naked DNA or 
using the same bacterium as a heterologous carrier expressing the antigen via a 
prokaryotic promoter (Weiss and Krusch, 2001; Weiss and Chakraborty, 2001). 
Delivering plasmids for genetic immunization with an attenuated bacterial carrier can 
combine the advantages and versatilities of both systems as already mentioned 
above. Moreover, the amount of plasmid required for bacterial-mediated DNA 
vaccination is astonishingly small compared to needle injection of naked DNA. This is 
most likely based on bacterial properties to target inductive sites of the immune 
system whereupon the antigen is expressed in immunologically relevant cells. 
Furthermore, bacterial cell wall components (e.g. lipopolysaccharides (LPS) from 
Gram-negative or lipoteichoic acids from Gram-positive bacteria) and unmethylated 
cytosine-phosphate-guanosine (CpG) motifs in the expression plasmid and/or 
bacterial chromosomal DNA provide their own adjuvant activity and can enhance 
and/or modulate immune responses (Krieg, 1999; Aderem and Ulevitch, 2000). In 
addition, these live bacterial vaccine strains can also deliver plasmids encoding 
therapeutic molecules (e.g. cytokines) or genes to complement genetic defects. 
In comparison to currently used viral and non-viral vectors, bacterial gene delivery 
vehicles include additional advantages. First of all, bacteria are cost-effective to 
produce, easy to store and to transport. The tissue tropism of bacteria can be 
employed to target genes to certain organs and the ability of some bacteria to spread 
from cell-to-cell might render them capable of targeting tissue layers inaccessible to 
other vector systems. Moreover, they are controllable by common antibiotics.  
However, bacteria-mediated gene transfer is yet confined mainly to preclinical 
studies either in vitro or in animal models. So far, gene transfer in vivo attempts were 
primarily directed towards vaccination strategies using Shigella flexneri or Salmonella 
spp. as carrier in experimental models (Darji et al., 1997, 2000; Flo et al., 2001; 
Fennelly et al., 1999; Pasetti et al., 1999; Shata et al., 2001), but also in clinical trials 
(Cunningham and Nemunaitis, 2001). Salmonella-mediated mucosal DNA 
vaccination has been extensively investigated using attenuated S. typhimurium as 
transfer system, but also S. typhi and S. choleraesuis have been tested in this 
context. 
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1.3.3 Main bacterial species employed for DNA transfer 
S. typhimurium 
This strain will be described in more detail below. 
S. typhi 
The strain S. typhi Ty21a (Germanier and Fuer, 1975), which is attenuated by a 
defect in the galactosidase degradation pathway due to a mutation in galE, is already 
licensed as typhoid fever vaccine for humans. Therefore, it was thought that 
attenuated strains of S. typhi cannot only serve as effective oral vaccines to prevent 
typhoid fever in humans (Wahdan et al., 1982; Levine et al., 1987, 1999), but also as 
live vectors to deliver foreign antigens to the immune system, either by the bacterial 
expression of antigens through prokaryotic expression plasmids or by delivery of 
foreign genes carried on DNA vaccines (Levine et al., 1997; Dietrich et al., 2000; 
Garmory et al., 2002). Since S. typhi is not virulent in mice, a proof of principle using 
these bacteria as carrier for DNA vaccination is limited to nasal or intraperitoneal 
administration. In the meantime, several genetically defined mutant strains were 
additionally developed like the strain CVD 908-htrA (aroC, aroD and htrA mutant) 
(Tacket et al., 2000) or CVD 915, which is attenuated by mutation in guaBA leading 
to a defect in the guanine biosynthesis pathway (Wang et al., 2001). 
Intraperitoneal application of S. typhi Ty21a carrying a plasmid encoding the 
nucleoprotein of measles virus to mice resulted in specific CTL responses (Fennelly 
et al., 1999). In a comprehensive study using a fragment of tetanus toxin, nasally 
administered S. typhi CVD 915 carrying a eukaryotic expression plasmid elicited 
higher antibody levels than did Salmonella carrying a prokaryotic expression plasmid 
or just intramuscular injection of the naked DNA vaccine (Pasetti et al., 1999). 
Interestingly, ampicillin treated mice showed low antibody responses after oral 
immunization with the Ty21a strain carrying a plasmid encoding the identical 
fragment of tetanus toxin (Woo et al., 2000). This suggests that S. typhi might enter 
via the intestine, when the animals are devoid of competing commensal bacteria. 
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Shigella flexneri 
The Gram-negative bacterium S. flexneri, which cause shigellosis in humans, enters 
the cytosol of host cells after phagocytosis and can deliver the plasmids directly to 
this intracellular compartment. Different metabolically attenuated mutants of  
S. flexneri have been demonstrated to successfully deliver plasmid DNA in vitro  
(Sizemore et al., 1995; Courvalin et al., 1995; Noriega et al., 1994, 1996; Powell et 
al., 1996). Since mice are not susceptible to gastrointestinal infection with S. flexneri, 
intranasal application was used to investigate its potential as carrier for DNA 
vaccines in these animals. Such Shigella-mediated gene-transfer in vivo has induced 
strong cellular and humoral immune responses against several antigens (Sizemore 
et al., 1995, 1997; Fennelly et al., 1999). 
E. coli 
Non-pathogenic strains of E. coli can also be employed as vehicles for DNA 
vaccination provided that they are rendered invasive (Courvalin et al., 1995; Grillot-
Courvalin et al., 1998, 1999). This system is mainly used in vitro so far, but also in 
vivo data were obtained more recently (Shiau et al., 2001; Radford et al., 2002, 
2003). 
Listeria monocytogenes 
L. monocytogenes is a Gram-positive, intracellular pathogen that enters the cytosol 
of the host cell. Attenuated strains of L. monocytogenes, defective in intracellular 
mobility and cell-to-cell spread (Dietrich et al., 1998), have been shown to be very 
effective delivery systems for targeting the heterologous antigens to both MHC  
class I and class II presentation pathways (Weiskirch and Paterson, 1997; Jensen et 
al., 1997; Guzman et al., 1995). The ability to stimulate the production of Th1-type 
cytokines make these bacteria especially attractive as delivery system for the 
development of vaccines against viruses, tumors and intracellular parasites (Pan et 
al., 1995; Slifka et al., 1996; Jensen et al., 1997; Ikonomidis et al., 1997; Paglia et al., 
1997). So far, efficient DNA transfer was only demonstrated in vitro in phagocytic and 
non-phagocytic cells (Hense et al., 2001; Krusch et al., 2002; Pilgrim et al., 2003). 
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1.4 Immunization with Salmonella typhimurium aroA- as carrier 
Effective protection against invasive Salmonella infections in man and animals is best 
elicited by live attenuated organisms rather than by killed vaccines (Collins, 1974). In 
addition, the proven ability to induce potent cell-mediated immunity, as well as 
humoral and local secretory responses to recombinant foreign antigens, makes these 
attenuated Salmonella particularly attractive as vehicle for the oral delivery of 
antigens from a variety of infectious microorganisms (Hormaeche, 1991). Moreover, 
attenuated S. typhimurium strains have been extensively studied as live vaccine 
carriers in mice as a model for the prediction of responses that would occur when 
humans are immunized orally with homologous strains of S. typhi. 
Salmonella typhimurium 
S. typhimurium is a Gram-negative, facultative anaerobic rod that belongs to the 
group of enterobacteria. Through liberation of endotoxin (lipopolysaccharides of the 
bacterial cell wall), which cause irritation of the mucous membrane, these facultative 
intracellular pathogen causes gastroenteritis (Schlegel, 1992). In the mouse model, 
S. typhimurium is the causative agent of murine typhoid fever and serves as 
experimental model for human typhoid caused by S. typhi (Collins, 1974; 
Hormaeche, 1979). 
Because of the extensive knowledge on the molecular genetics and physiology of 
many strains, Salmonella spp. are particularly suited as delivery system for DNA 
vaccines. In addition, a large body of documentation already exists pertaining to their 
utility as heterologous antigen carriers capable of inducing protective immune 
responses (Newton et al., 1989; Fairweather et al., 1990; Roberts and Socket, 1994; 
reviewed by Chatfield et al., 1994). Safe attenuated strains of Salmonella are 
available and are already in use as vaccines in man and farm animals (Germanier 
and Fuer, 1975; Hassan and Curtiss, III, 1996; Steinbach et al., 1996; Fox et al., 
1997; Mastroeni et al., 2000). 
A fundamental feature of pathogenesis of Salmonella that contributes to their 
success as live vector is their ability to invade the intestinal mucosa. To induce a 
mucosal immune response or a systemic infection, orally applied Salmonella first 
have to pass across the mucosal surfaces of the gastrointestinal tract. Lymphoid 
follicles in mucosal lymphoid tissues of the small intestine and colon are covered by 
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the follicle-associated epithelium (FAE). This FAE contains M cells, a unique 
epithelial cell type specialized for transepithelial transport of macromolecules, 
particles, and microorganisms (Neutra et al., 1996a,b; Clark et al., 1994) (Fig. 1.1). 
Such specialized cells lack the mucin barrier, the rigid brush border cytoskeleton and 
digestive properties of other mucosal epithelial cells. Instead, they can bind and 
endocytose macromolecules and microorganisms, which are then transcytosed intact 
and delivered to the underlying lymphoid tissue. The M cell basolateral membrane is 
deeply invaginated to form a large intraepithelial pocket containing T lymphocytes  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1: Structural features of Peyer´s Patches. The lymphoid follicle of 
Peyer´s patches is covered by the follicle-associated epithelium (FAE)  that
contains M cells specialized for transepithelial transport of macromolecules, 
particles and microorganisms. The underlying follicle consists of large central
dome of B lymphocytes surrounded by smaller numbers of T cells.
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(including CD4+ helper cells and CD45RO+ memory cells), B lymphocytes, 
macrophages (Neutra et al., 1996a) and DCs (Hopkins et al., 2000). Several 
pathogenic bacteria causing systemic infections, including Salmonella, target these 
M cells to gain access to the body (Neutra and Kraehenbuhl, 1992). The main 
entrance of invasive S. typhimurium are the Peyer´s patches (PP) of the ileum, 
appearing as aggregated mucosal lymphoid follicles, and possibly the lymphoid 
patches of the appendix (Carter and Collins, 1974; Hohmann et al., 1978). In 
addition, transepithelial invasion of enterocytes has also been observed (Ohl and 
Miller, 2001). 
Jones et al. (1994) showed that Salmonella adhere rapidly and selectively (but not 
exclusively) to M cells. The following invasion initiates signal transduction events that 
are associated with loss of microvilli (Takeuchi, 1967; Kohbata et al., 1986) and 
cause active ruffling of the M cell apical surface. Further, these modifications are 
accompanied by rapid disassembly of the apical cytoskeleton in vivo as well as in 
vitro (Bliska et al., 1993; Finlay et al., 1991; Francis et al., 1992, 1993; Jones et al., 
1993, 1994; Clark et al., 1994; Neutra et al., 1996a). Such events finally result in 
engulfment of bacteria by macropinocytosis into membrane-bound vesicles 
(Takeuchi, 1967; Neutra et al., 1996a,b; Clark et al., 1994). Rapid transcytosis 
follows and Salmonella are transported into the intraepithelial pocket. Thus, they 
directly reach the organized mucosa-associated lymphoid tissue (MALT), the 
inductive site of mucosal immune responses (Neutra and Kraehenbuhl, 1994). There, 
the Salmonella are taken up by professional phagocytes (including macrophages and 
DCs), which induce local secretory responses through activation of IgA secreting B 
cells and probably elicit systemic responses after migration into lymphnode and 
spleen. 
S. typhimurium strains that are commonly used as live vectors have been attenuated 
by mutations in: 
- cya (encoding adenylate cyclase) and crp (encoding the cyclic AMP receptor 
protein), that together comprise a global regulatory system affecting multiple 
virulence and housekeeping genes (Curtiss, III and Kelly, 1987); 
- aroA, aroC or aroD, encoding enzymes in the biosynthesis of aromatic 
metabolites (Dougan et al., 1988); 
- phoP, phoQ, a regulatory system controlling genes that allow Salmonella to 
survive within phagolysosomes in macrophages (Miller et al., 1989); 
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- htrA, encoding a stress response protein that functions as a serine protease 
(Chatfield et al., 1992b). 
Such attenuated Salmonella complete the early steps in pathogenesis. They gain 
access to APCs in the gut-associated lymphoid tissue (GALT) via M cells of the 
Peyer´s patches (Neutra et al., 1996a; Siebers and Finlay, 1996) and migrate into 
lymphnodes and spleen. But they do not cause adverse clinical responses or 
detectable bacteremia. With this kind of delivery, cell-mediated, humoral and local 
secretory immune responses of both mucosal as well as systemic immunity are 
induced.  
S. typhimurium aroA- 
Salmonella, unlike vertebrates, cannot assimilate exogenous folate and have to 
synthesize it from p-aminobenzoic acid (pAB). 2, 3-dihydroxybenzoate (DHB) is the 
precursor of enterocholin, the iron-aquisition compound of gram-negative bacteria. 
Salmonella synthesize pAB and DHB from chorismate, the final product of the 
aromatic biosynthetic (aro) pathway (Hoiseth and Stocker, 1981). Lesions in the gene 
aroA cause a complete block at any step of the chorismate pathway rendering  
S. typhimurium auxotrophic for these two compounds, which are not available in 
vertebrate tissues. Such auxotrophic mutants are non-virulent in the immuno-
competent host ( Bacon et al., 1950, 1951; Yancey et al., 1979). 
The aroA gene encodes the enzyme 5-enolpyruvylshikimate-3-phosphate synthase, 
vital for a functioning chorismate pathway and essential to bacteria for the 
biosynthesis of the aromatic ring (Pittard et al., 1990). Insertion of the transposon 
Tn10 into the gene aroA (Kleckner et al., 1975; Kleckner, 1977) generates aromate-
requiring derivates of virulent S. typhimurium strains. The transposon Tn10 encodes 
the tetracycline-resistance gene and has the tendency to cause DNA alterations 
within the transposon itself. Many such deletion or deletion-inversion events cause 
both, inability of the affected gene to revert to the wild-type form and loss of 
tetracycline resistance (Hoiseth and Stocker, 1981). 
These live attenuated Salmonella have a very limited invasive potential, grow slowly 
in vivo and finally die due to their attenuation. In this way, they just cause a mild, low-
grade infection, after which bacteria are cleared by the immune system from the 
tissues (Hormaeche, 1991). However, they can survive long enough to induce an 
efficacious immune response (Hoiseth and Stocker, 1981; Stocker, 1988). Mice 
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which received such attenuated S. typhimurium as live vaccine are protected against 
challenge with a virulent strain (Dougan et al., 1994). Moreover, live Salmonella 
typhimurium aroA- directs the cell-mediated immune response into a Th1 response, 
which is advantageous for clearance of intracellular bacteria (Darji et al., 1997; 
VanCott et al., 1998). Administration of aroA mutant strains is more efficacious than 
vaccination by injection of killed Salmonella, which confers only poor protection 
against reinfection with a virulent Salmonella strain (Robson and Vas, 1972). Similar 
results were observed in cattle (Smith et al., 1984; Jones et al., 1991), sheep 
(Mukkur et al., 1987) and chickens (Barrow et al., 1990; Cooper et al., 1990). 
Microorganisms with genetically defined, non-reverting mutations in attenuating 
genes are considered to be safe live vaccines since they have been engineered to 
require essential metabolites not available in vertebrate tissues. For example, 
attenuation due to a requirement for an unavailable essential metabolite could be a 
safety factor if aro mutants were administered to subjects with defective immunity 
(Hormaeche, 1991). However, S. typhimurium aroA- was shown to be partly virulent, 
since it is still lethal in mice in which interferon g has been deleted (Paglia et al., 
2000). Safety of live vaccines can further be increased by introducing more than one 
attenuating lesion (Dougan et al., 1988; Miller et al., 1989; Fairweather et al., 1990). 
Since Salmonella strains are highly immunogenic, if they are administered orally, live 
attenuated Salmonella vaccines can serve not only as oral vaccines against invasive 
salmonellosis in man and animals but are also attractive for the development of 
multivalent vaccines, which are based on the expression of heterologous antigens in 
these strains (Chatfield et al., 1995). 
1.5 S. typhimurium aroA- as carrier of heterologous antigens 
The aroA- mutants of S. typhimurium with genetically defined attenuations are safe 
live vaccines and can serve as vehicles for heterologous antigens of viruses, 
parasites, bacteria and other immunogens. In mouse infection models, recombinant 
S. typhimurium aroA- were successfully employed for hepatitis B (Schodel et al., 
1994a; Hopkins et al., 1995; Londono et al., 1996), herpes simplex (Chabalgoity et 
al., 1996), malaria (Sadoff et al., 1988; Schodel et al., 1994b; Haddad et al., 1995), 
Shistosoma mansoni (Khan et al., 1994), tetanus (Fairweather et al., 1990; Chatfield 
et al., 1992a; Dunstan et al., 1998) and streptococcus (Redman et al., 1996; 
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Hajishengalis et al., 1996). Expression of HIV antigens by  
S. typhimurium was shown to induce specific immune responses in mice (Charbit et 
al., 1993: Fouts et al., 1995). 
1.6 Oral genetic vaccination with Salmonella aroA- 
The use of S. typhimurium as carrier for oral transgene vaccination was first 
demonstrated with the two virulence factors listeriolysin O (LLO) and ActA of  
L. monocytogenes, and ß-galactosidase of E. coli as antigens in the mouse model 
(Darji et al., 1997). In the meantime, oral DNA vaccination with S. typhimurium as 
carrier has been successfully extended to Chlamydia trachomatis (Brunham and 
Zhang, 1999), herpes simplex virus 2 (Flo et al.,2001), hepatitis B virus (Woo et al., 
2001; Zheng et al., 2001), and hepatitis C virus (Wedemeyer et al., 2001), Yersinia 
pestis (Garmory et al., 2003) as well as to tumor models (Paglia et al., 1998; Lode et 
al., 2000; Niethammer et al., 2001; Xiang et al., 2000, 2001; Weth et al., 2001; Zoller 
and Christ, 2001). Furthermore, Salmonella-mediated oral DNA immunization was 
applied in a study for the treatment of the fungus Penicillium marneffei (Wong et al., 
2002). Apart from the possibility to prevent infectious disease, S. typhimurium-
mediated gene transfer has been also employed to complement monogenic defects 
(Montosi et al., 2000; Paglia et al., 2000) and to transfer therapeutic molecules 
(Urashima et al., 2000; Yuhua et al., 2001). The extraordinary versatility of 
Salmonella live vectors demonstrated here makes them a promising live DNA 
vaccine delivery system. Although, human clinical trials with DNA vaccines delivered 
by attenuated Salmonella have not yet been undertaken, it is expected that clinical 
trials with constructs carrying P. falciparium, HIV and measles DNA vaccines will be 
initiated soon (Levine et al., 2002). 
Possible mechanism of Salmonella-mediated gene-transfer 
The method of oral genetic vaccination with attenuated Salmonella as carrier is most 
likely based on the induction of adaptive immune responses as proposed by Darji et 
al. (1997, 2000). Orally administered S. typhimurium aroA- reach the host via M cells 
of the Peyer´s patches and are taken up by macrophages and dendritic cells 
(Hopkins et al., 2000) in the intraepithelial pocket where they reside in the phagocytic 
vacuoles (Fig.1.2; Fig. 1.3). These phagocytic cells are activated by the pathogen 
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and DCs might migrate probably into lymphnodes and spleen via the bloodstream or 
lymph fluid. During this time, the intracellular bacteria die after a view round of 
replication due to their attenuation and release the eukaryotic expression vector (Fig. 
1.2). 
S. typhimurium, unlike e.g. Shigella, remains in the phagosomal compartment of the 
host cell, where it releases the plasmid DNA after bacterial lysis. How the transfer of 
plasmid DNA into the cytoplasm of host cells is achieved is still unclear. Possibly, the 
bacteria encode a machinery to transfer macromolecules, particularly plasmid DNA, 
into target cells as it was shown for bacterial proteins injected into the cytosol by type 
III secretion systems in several Gram-negative bacteria (Galan and Collmer, 1999). 
In contrast, the transfer of DNA by bacterial ghosts has been demonstrated (Lubitz, 
2001), rendering an active mechanism encoded by the microorganism highly unlikely. 
In addition, cell specificity has been observed for different bacterial species in their 
ability to transfer DNA from the phagosomal compartment. For example,  
S. typhimurium exclusively transfers DNA into primary murine and human 
macrophages and human dendritic cells in vitro (Darji et al., 1997; Montosi et al., 
2000; Dietrich et al., 2001), whereas transfer into established cell lines of different 
origin was extremely inefficient (Darji et al., 1997; Grillot-Courvalin et al., 2002). 
Thus, it is more likely that particular host cell specific pathways exist that are 
exploited by the different bacterial species (Weiss, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.: 1.2: Schematic representation of Salmonella-mediated gene-transfer after
oral immunization (Darji et al., 1997).
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After transfer into the cytosol, the plasmid vector reaches the nucleus, where it is 
transcribed. This leads to the expression of non-secretory antigens in the cytosol of 
the host cell. In turn, specific cytotoxic T cells will be stimulated by the activated 
APCs (Fig. 1.2). 
Upon infection of activated macrophages, Salmonella induce programmed cell death 
(Chen et al., 1996; Monack et al., 1996) through two different pathways. The 
immediate type is mainly induced by virulence factors of pathogenicity island I (Hersh 
et al., 1999) and is essential for the dissemination of Salmonella from the Peyer´s 
patches to the deep organs (Monack et al., 2000). In comparison, the delayed cell 
death is primarily dependent on virulence factors of pathogenicity island II (Monack et 
al., 2001). This programmed cell death after infection by Salmonella shares features 
of apoptosis as well as of necrosis (Brennan and Cookson, 2000) and was described 
as pyroptosis by (Cookson and Brennan, 2001). Thus, intracellular antigens are 
possibly released after Salmonella-mediated oral DNA vaccination from infected 
macrophages and might be acquired by neighboring DCs, which could present the 
antigen via MHC class II to stimulate helper T cells as well as via MHC class I to 
activate cytotoxic T cells. Free antigen could also be responsible for the induction of 
antibody responses. In addition, it is possible that neighboring DCs take up the 
complete dying macrophages and re-present the antigens expressed by this cell via 
MHC class I and II via cross-presentation (Heath and Carbone, 2001) (Fig. 1.3).  
Activation of CTL and helper T cells can occur not only locally in the Peyer´s patches, 
but also in deep lymphoid organs, including mesenteric lymphnodes and spleen, after 
migration of antigen-presenting dendritic cells (Darji et al., 2000, unpublished; 
reviewed by Weiss, 2003). Another alternative for the induction of systemic immune 
responses after administration of plasmid carrying Salmonella was suggested by the 
recent finding that dendritic cells in the lamina propria can extend dendrites into the 
gut lumen to sample antigen (Rescigno et al., 2001). Thus, the recombinant 
Salmonella might be sampled by such DCs, which could in turn transport after in vivo 
transfection the antigen to the lymphoid organs and induce the immune responses. 
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Advantages of Salmonella-mediated DNA transfer 
Favorable for this kind of vaccination is that the recombinant plasmids encoding the 
heterologous antigen are first constructed in lab strains of E. coli and can be 
introduced afterwards directly into Salmonella (e.g. by electroporation) without further 
manipulation, since both bacterial species are closely related. 
Bacterial endotoxin and DNA sequence motifs can serve as adjuvants and enhance 
the immune response. The helper T cell response evoked by this kind of genetic 
immunization with S. typhimurium aroA- seems to be strongly biased to a Th1-
response as was expected for this specific bacterial carrier (Darji et al., 1997). 
Salmonella-mediated mucosal DNA vaccination elicited cytotoxic and helper T cells 
as well as specific antibodies even after a single application and was far superior to 
Fig. 1.3: Mechanisms of antigen presentation after Salmonella-mediated gene-
transfer. Lysis of Salmonella after phagocytosis by APCs (macrohages and DCs) 
leads to transfer of the eukaryotic plasmid into the nucleus of the host cell where the 
antigen is transcribed leading to direct antigen expression in the cytosol. In addition, 
dendritic cells might take up dying macrophages and re-present antigens via cross-
presentation.
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oral application with an equal amount of Salmonella expressing high amounts of 
heterologous antigen under control of a prokaryotic promoter (Darji et al., 1997). 
Additionally, only recombinant Salmonella carrying a eukaryotic expression plasmid 
could also induce T cell memory (Darji et al., 2000). Furthermore, Salmonella 
carrying an expression plasmid encoding listeriolysin O protected mice against a 
lethal challenge with L. monocytogenes (Darji et al., 1997). 
However, despite this strong induction of T cells and specific IgG antibodies after 
mucosal administration, hardly any antigen specific IgA antibodies could be detected 
(Darji et al., 2000, unpublished). Moreover, the induction of an antibody response in 
general (including IgG) is only possible under optimal conditions (Darji et al., 2000). 
One problem might be that the Salmonella aroA- strain, that is currently mainly used, 
is dying very quickly when containing high copy number plasmids (Garmory et al., 
2002b) and thus only few cells might be transfected or only few plasmids might be 
transferred. Antigen expression also might be limited by an efficiently induced 
programmed cell death of the cells infected by these Salmonella. Although Urashima 
et al. (2000) could demonstrate many transgene expressing cells in the Peyer´s 
Patches after Salmonella-mediated DNA transfer, such cells might not support 
efficient antibody production and/or the switch of B cells to IgA. Therefore, further 
improvements are required to generate strong local antibody responses in addition to 
the systemic response. 
1.7 Optimization of bacterial DNA delivery systems 
Depending on the nature of the invading pathogen, specific host responses are 
required for protection and clearance of these infectious agents. Therefore, selection 
of the most adequate strategy to stimulate the required immune response is essential 
for vaccine development, as mentioned before. In this respect, the exploitation of 
attenuated bacteria as antigen delivery system for DNA vaccines offers several tools 
to stimulate and modulate the appropriate type of immune response that is needed. 
The bacterial carrier and the antigen-coding plasmid are different entities. Modulation 
and specific targeting of the immune response should be possible by either choosing 
or engineering a proper bacterial carrier strain, alternatively by modifying the plasmid 
(e.g. by co-expression of cytokines or co-stimulatory molecules) itself. 
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1.7.1 Vector optimization 
Manipulation of plasmid DNA vectors to achieve increased levels of expression in 
vivo is a laudable goal of DNA vaccine development. This approach is particularly 
attractive since changes of the vector sequence do not affect the formulation of the 
vaccine itself unlike other potential approaches that would involve additional 
components. Hence, they would increase the complexity of the vaccine (Ulmer et al., 
1996). 
Since it is generally believed that the level of expression in vivo obtained after DNA 
vaccination correlates with the immune response generated, there are several 
approaches to improve gene expression. These approaches include optimizing gene 
regulatory elements within the plasmid backbone or modifying the plasmid backbone 
itself to enhance gene expression. Thus, several possibilities exist to improve the 
plasmid vector: 
Codon usage 
Since codon bias has been detected in several species, the use of selective codons 
in a particular gene correlates with efficiency of gene expression (Lewin, 1994). For 
example, using an expression cassette for gp120 of HIV that was codon optimized 
for human vaccination already a single application induced a strong CD8+ T cell 
response in spleen and Peyer´s patches compared to a non-codon optimized 
construct (Shata and Hone, 2001). Therefore, optimization of codon usage for 
eukaryotic cells enhanced antigen expression and subsequently led to enhanced 
CTL and protective immunity (Uchijima et al., 1998; Andre et al., 1998; Vinner et al., 
1999). 
Regulatory elements 
Specific modifications to a vector that could increase overall protein expression 
include particular combination of promoter and terminator (Montgomery et al., 1993; 
Liang et al., 1996). Virally derived promoters, especially the CMV immediate early 
enhancer-promoter, provided the strongest gene expression in vivo compared to 
eukaryotic promoters (Manthorpe et al., 1993; Cheng et al., 1993). On the other 
hand, viral promoters can be down-regulated by IFNg and TNFa, which might be 
induced upon immunization. This could lead to down-regulation of antigen expression 
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(Qin et al., 1997). Furthermore, the particular promoter chosen to drive expression of 
the recombinant antigen can influence the quality of immune responses (Medina et 
al., 2000). 
The inclusion of enhancer elements such as intron A region of the cytomegalovirus 
promoter results in optimal gene expression due to splicing of the mRNA transcript 
(Chapman et al., 1991). Further, transcriptional termination elements (e.g. from the 
rabbit ß-globin gene) that confer mRNA stability have been shown to enhance gene 
expression (Norman et al., 1997). Although it is in principle desirable to develop 
vectors for high level expression of protein, there may be also some mitigating 
factors. As examples, high levels of a protein that is toxic to cells could limit the 
duration of expression, and the expression of a protein that has effects on other cells 
(including cells of the immune system) could decrease immune responses directed 
against it (Ulmer et al., 1996). 
Recently, strategies taking advantage of an alphaviral replicon to create an in vivo 
amplification system to improve DNA vaccine vectors were described (Tubulekas et 
al., 1997; Berglund et al., 1996). This type of construct can efficiently trigger cellular 
and humoral immune responses, although the alphaviral mediated expression is 
transient and lytic, which could be advantageous in terms of biosafety risks and 
tolerance-induction concerns (Berglund et al., 1998). 
Plasmid stability 
So far, the biggest problem seems to be the instability of the vector system. The use 
of high copy number plasmids most likely also influences the stability of the 
recombinant Salmonella in culture and in vivo (Garmory et al., 2002b). Usually 
recombinant high copy number plasmids carry antibiotic resistance markers to 
facilitate identification and to keep selective pressure in favor of plasmid retention. 
Such plasmids are unstable in vitro and in vivo in the absence of a stabilizing 
antibiotic, but can be stabilized in vitro by addition of the appropriate compound. 
Stability in vivo, however, is more critical and less certain. Therefore, different 
approaches have been suggested to address the issue of plasmid stability and to 
avoid the necessity for a stabilizing antibiotic. On the one hand, it was demonstrated 
that chromosomal integration of the heterologous antigen into Salmonella stabilizes 
antigen expression but also results in lower antigen concentrations (Hone et al., 
1988; Strugnell et al., 1990). Studies by Cardenas & Clements revealed that the 
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intensity of immune responses against the B subunit of the heat-labile toxin (LTB) of 
enterotoxic E. coli after chromosomal expression were comparably weaker, although 
the construct was absolutely stable during the experiment (Cardenas and Clements, 
1993). These data indicate that the amount of antigen that primes the gut-associated 
lymphoid tissue is very important for the development of an immune response 
against a foreign antigen and should be as high as possible. 
Another possibility how stability of the expression construct can be reached, was 
demonstrated by the use of the asd+/Dasd balanced lethal system (Nakayama et al., 
1988; Curtiss, III et al., 1990). Only Salmonella carrying a plasmid that complements 
the gene defect in the bacterium are able to survive. This combination of expression 
vector and mutant strain certainly eliminates the need for stabilizing antibiotics, but 
does not solve the problem of a general instable plasmid. The features of the 
plasmids and antigens that are expressed constitutively might diminish the vitality of 
the Salmonella carrier. The expression of heterologous antigens from in vivo 
inducible promoters was already shown to enhance stable expression and 
immunogenicity of a number of foreign genes by S. typhimurium (Chatfield et al., 
1992a; Hohmann et al., 1995). Similarly, the maintenance of a plasmid by bacteria 
during growth can also be influenced by the copy number of the expression plasmid, 
its size and complexicity or the expression level of the heterologous antigen. The 
relationship between plasmid instability and the copy number had been observed in 
previous studies (Coulson et al., 1994; Garmory et al., 2002, 2003). High copy 
number plasmids are rapidly lost from the bacteria, whereas a decrease in copy 
number reduces the level of metabolic burden and consequently improve plasmid 
retention in Salmonella. Since the copy number is usually regulated by the plasmid 
origin of replication (ori), expression plasmids carrying different low copy number 
ori´s should result in improved plasmid stability. 
Targeting 
The removal of elements not essential for eukaryotic expression, such as those 
contained in multi-purpose expression vectors, could also be advantageous for 
improved gene expression. A plasmid may also be engineered in the way that the 
encoded protein is either secreted or localized to the interior of the cell (Gurunathan 
et al., 2000). This might have dramatic effects of whether an antibody response is 
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elicited or not. Using N-terminal ubiquitination signals, which target the protein to 
proteosomes could enhance the delivery into the MHC class I pathway, thus inducing 
a stronger CTL response (Wu and Kipps, 1997). 
CpG motifs 
In addition, the modification of vectors could inadvertently introduce specific 
nucleotide sequences (e.g. CpG-motifs) that have modulatory effects on immune 
cells and can act as adjuvant by stimulation of these cells via Toll-like receptor 9 
(TLR 9) to contribute to the immunogenicity of DNA vaccines. GC-rich DNA from 
bacterial sources was shown to stimulate natural killer (NK) cells (Yamamoto et al., 
1992), B lymphocyte activity resulting in antibody production (Messina et al., 1991; 
Krieg et al., 1995b) and can directly induce professional APCs to secrete cytokines 
such as IFNg, IL-12, IL-6, IL-18 and TNFa (Klinman et al., 1996; Stacey et al., 1996; 
Jakob et al., 1998). Likewise, CpG oligodeoxynucleotides can stimulate primary T 
cells in the absence of antigen-presenting cells (Bendigs et al., 1999). After 
substitution of a kanR-selectable marker for a CpG-containing ampR gene in a  
ß-galactosidase-encoding plasmid, the altered plasmid induced higher IgG antibody, 
CTL and IFNg production (Sato et al., 1996). The same effect was observed, when 
additional CpG motifs were introduced into the plasmid backbone, suggesting that 
the innate immune response stimulated by CpG motifs could promote antigen-
specific humoral and cell mediated immunity (Klinman et al., 1997, 1999; Roman et 
al., 1997; Krieg et al., 1998). The use of additional CpG motifs may decrease the 
amount of vaccine required to induce an immune response rather than increase the 
absolute magnitude of a response (Gurunathan et al., 2000). 
Expression of immunostimulatory DNA adjuvants, such as open reading frames for 
cytokines and costimulatory molecules, may also be useful to enhance or modulate 
immune responses induced by DNA vaccines in vivo (Ulmer et al., 1996; Gurunathan 
et al., 2000). Recent work by Krieg et al. (1998) demonstrated that eliminating 
suppressive motifs (tandem repeats of GpC) from the plasmid backbone of a DNA 
vaccine improved its immunogenicity. These observations display the complex 
interaction between DNA sequence motifs and the immune system. In contrast, the 
CpG motifs that induce optimal stimulation in mice (see above) are less effective on 
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cells of primate origin and sequence motifs optimally active in humans will have to be 
introduced when such types of vaccines enter the clinic. 
Cytokines and Costimulatory molecules 
Cytokines and costimulatory cell surface molecules play a crucial role in generation 
of effector T-cell subsets. Hence, several groups have exploited these molecules, 
encoded by plasmid DNA, to enhance or bias the immune response generated by 
DNA vaccination (reviewed by Gurunathan et al., 2000). Yuhua et al. (2001) 
demonstrated that oral cytokine gene therapy with IL-12 and GM-CSF (granulocyte-
macrophage colony-stimulating factor) using live attenuated Salmonella significantly 
protects mice against two unrelated tumors. A dual-function DNA vaccine encoding a 
carcinoembryonic antigen fused with the costimulatory CD40 ligand trimer induced  
T cell-mediated protection against murine colon carcinoma (Xiang et al., 2001). 
Furthermore, the delivery of plasmid encoded cytokines by live attenuated 
Salmonella was able to modulate the immune responses in a variety of experimental 
models, i.e. influencing cytokine and antibody production to bystander co-
administered heterologous antigens, modifying the immune response during a 
parasitic infection, and extending the life expectancy in melanoma-bearing mice 
(Rosenkranz et al., 2003). 
Multivalent vaccines 
Expression of two or multiple genes in the same cell, bicistronic or multicistronic 
vectors with internal ribosomal entry site (IRES) could be particularly useful in 
constructing multivalent vaccines from two or more different antigens from the same 
or different pathogens (Wild et al., 1998) or an antigen in combination with a cytokine 
or costimulatory molecule. 
Moreover, co-delivery of two compatible eukaryotic expression plasmids encoding 
either the glycoprotein D gene of pseudorabies virus (PrV gD) or prothymosin as 
adjuvant together in the same Salmonella choleraesuis has been demonstrated to 
confer protective immunity against pseudorabies and enhance the vaccine efficacy 
compared to the application of Salmonella carrying the PrV gD expression plasmid 
alone (Shiau et al., 2001). Thus, the use of compatible plasmids in the same 
bacterium is likely to provide the possibility of delivering more than one antigen either 
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from the same or of different pathogens or to coadminister cytokines or costimulatory 
molecules together with the antigen. 
Thus, optimization might be possible at various properties of the expression plasmid 
and a systematic approach is required to find out the optimal combination for a 
particular vaccine to elicit appropriate protective responses. 
1.7.2 Optimization of the bacterial carrier 
Many of the bacteria that target inductive sites and cells of the immune system 
display regional tropisms often manifested as colonization of specific mucosal 
surfaces or internal organs. The class of immune response that is evoked depends 
not only on the general features of the bacterial carrier, but also on the nature of the 
specific mutations affecting its virulence properties (Dunstan et al., 1998; Medina and 
Guzman, 2001). Depending on the attenuating mutations, strains may differ in their 
capacity to elicit antibody or cell-mediated immune responses (VanCott et al., 1998; 
Medina et al., 1999). For example, S. typhimurium aroA- mutants elicit strong specific 
antibody and T helper cell responses, since Th1 cells and IFNg are required for 
clearance of the aroA- strain. In comparison, a PhoP- null phenotype promotes potent 
innate immune responses of macrophages by involving CD14 and TLR4 as well as 
iNOS/O2-. Thus innate responses are sufficient for host defense (VanCott et al., 
1998). 
This demonstrates that the choice of the attenuated Salmonella strain is critical. The 
class of immune response elicited against the heterologous antigen is influenced by 
the dominant type of immunity promoted by the carrier itself. Therefore, similar to 
testing properties of the plasmid, systematic testing of variant Salmonella strains with 
regard to immunmodulating properties is essential for the development of improved 
oral vaccines. 
1.8 Aims of this work 
Within the framework of this thesis, the vector system currently used for Salmonella-
mediated gene transfer should be improved, on the one hand, by the use of different 
eukaryotic promoters and, on the other hand, on the basis of increased plasmid 
stability in Salmonella. 
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At present, all studies in this laboratory were performed using the commercially 
available high copy number plasmid pCMVß encoding the model antigen  
ß-galactosidase or substituted by other relevant antigens like listeriolysin from  
L. monocytogenes or LACK (Leishmania homologue of receptors for activated C 
kinase) from Leishmania major. Although these constructs could stimulate a strong 
cytotoxic as well as helper T cell response, the induction of an antibody response is 
only possible under optimal conditions and is primarily systemic and not mucosal as 
might have been expected for a mucosally applied vaccine (Darji et al., 1997, 2000). 
Although the cytomegalovirus immediate early promoter and enhancer (CMV 
promoter) is a strong promotor for antigen-expression, several groups have shown 
that strong, constitutive, viral promoters do not cause long-term transgene 
expression in vivo (Scharfmann et al., 1994; Challita and Kohn, 1994; Rettinger et al., 
1994). Moreover, transgene expression from viral promoters is inhibited by cytokines 
like IFNg and TNFa (Qin et al., 1997). These observations might interfere with the 
ability of recombinant S. typhimurium aroA- to induce local antibodies and T cell 
memory after only a single administration, since aroA- mutants especially stimulate 
IFNg-secretion for host defense. To circumvent this problem, different eukaryotic 
promoters should be constructed. Their potential to drive antigen expression after 
oral transgene immunization with S. typhimurium aroA- and subsequently to generate 
specific immune responses should be compared to the original pCMVß plasmid. 
Therefore, the CMV promoter in the eukaryotic expression vector pCMVß was 
substituted by the human lysozyme promoter (Dighe et al., 1995; Clarke et al., 1996), 
the human elongation factor 1 alpha (Uetsuki et al., 1989; Kim et al., 1990), the 
ubiquitin promoter (Nenoi et al., 1996) or the CD11c promoter (Lopez-Cabrera et al., 
1993). In addition, the human interferon regulatory factor 1 (IRF-1) gene promoter 
(Sims et al., 1993) was also included, which is activated by IFNg. Hence, the IRF-1 
promoter should be up-regulated by IFNg that is produced upon immunization for 
host defense against S. typhimurium aroA-.  
From this first set of experiments, it became obvious that first of all the bacterial 
delivery system had to be optimized, since all recombinant strains rapidly lost their 
plasmids in culture. 
One basic problem was that the currently used S. typhimurium aroA- strain is dying 
very quickly when harboring high copy number plasmids (Garmory et al., 2002). 
1 Introduction 37 
 
Thus, only few cells might be transfected or only few plasmids are transferred 
resulting in limited antigen expression and therefore an insufficient stimulation of 
humoral responses. Along this line, another problem appears to be the stability of the 
vector system, since the copy numbers of the plasmids that are employed so far 
influence the stability of the recombinant bacteria in culture as well as in vivo 
(Coulson et al., 1994). A decrease in copy number should reduce the level of 
metabolic burden, thus plasmid retention in Salmonella should be obtained with 
plasmids of low copy number. 
The copy number is usually regulated by the plasmid origin of replication (ori). 
Therefore, new expression plasmids on the background of the pCMVß vector were 
designed containing different low copy number ori´s. Transformation of Salmonella 
with such vectors should result in improved plasmid stability and possibly an 
increased level of antigen expression and immune responses. 
The new plasmids were designed to consist of cassettes that could be easily 
exchanged when required. In the following, the pUCori of pCMVß was exchanged 
against the low copy number ori´s pMB1, p15A and the very low copy number ori 
pSC101. These newly constructed vectors were compared with the conventionally 
used pCMVß with regard of plasmid stability in vitro in the absence of a stabilizing 
antibiotic as well as in vivo. Using these strains, induction of cellular and humoral 
immune responses against the model antigen ß-galactosidase should be analyzed 
and compared after single or multiple administrations of these recombinant 
Salmonella strains. In addition, the capacity of these strains to protect mice against a 
lethal dose of Listeria monocytogenes should be examined using listeriolysin (LLO) 
as antigen. These protection studies are particular important, because single 
administration of the original recombinant Salmonella only partially protected mice 
(Darji et al., 1997, 2000). 
Since the different ori’s should be able to coexist in one and the same bacterium  
S. typhimurium aroA- should be transformed with two plasmids containing compatible 
origins of replication and plasmid retention in Salmonella in vitro as well as in vivo 
should be investigated. To facilitate the identification of both plasmids, the ampicillin 
resistance marker (AmpR) should be replaced by a tetracycline resistance marker 
(TetR). Using ß-galactosidase and LLO as antigens in the two compatible plasmids, 
immune responses, that will be evoked after vaccination against both antigens 
simultaneously, should be investigated. 
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The opportunity to deliver two compatible plasmids at once within the same 
bacterium should offer a simple and versatile tool to enhance and/or modulate the 
immune responses by co-delivering additional antigen, cytokines or costimulatory 
molecules. Thus, a step towards a second generation of Salmonella-based oral DNA 
vaccine should be taken with these new strains. 
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2 Materials 
2.1 Bacteria 
2.1.1 Eschericha coli strains 
The E. coli strain TOP 10 (Invitrogen, Groningen, The Netherlands) was used for 
general cloning of plasmids. 
2.1.2 Salmonella typhimurium strains 
The auxotrophic, non-virulent S. typhimurium aroA- strain SL7207 (S. typhimurium 
2337-65 deriv., hisG46, DEL407 [aroA::Tn10 {Tc-s}]; kindly provided by Dr. B. A. D. 
Stocker, Stanford, USA) was used as carrier for the in vitro assays as well as for the 
in vivo studies in the mouse model. 
2.1.3 Listeria monocytogenes strains 
The wild-type strain L. monocytogenes EGDe, serotype 1/2a (Leimeister-Wächter 
and Chakraborty, 1989) was used for in vivo protection assays. 
 
2.2 Cell lines 
BHK-21:  fibroblast-like cell line; generated from kidney cells of asexual 
hamsters (BHK = baby hamster kidney) 
HEp-2:  adherent, epithelial HeLa contaminant, derived from human 
(Homo sapiens), ATCC CCL-23. 
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2.2.1 Mouse strains 
6-to 8-week-old female BALB/c (H-2d) mice were used. Mice were maintained from 
Harlan Winkelmann (Borken, Germany). 
2.3 Culture Media 
2.3.1 Culture media for bacteria 
2.3.1.1 LB-Broth 
Luria Bertani broth (LB, Sambrook et al., 1989) was utilized for culture of E. coli und 
S. typhimurium aroA- strains in LB-broth or on LB-agar plates. For in vivo studies, S. 
typhimurium aroA- was grown in LB-broth supplemented with 1.5% final NaCl. 
Recombinant bacteria were cultivated by addition of either 100 µg/ml ampicillin or  
25 µg/ml tetracycline or a combination, where required. 
LB-broth:    10 g bacto-trypton; 5 g yeast extract; 10 g NaCl; 
H2O ad 1000 ml 
Agar plates:    For production of agar plates, LB-broth was 
supplemented with 15 g/l agar. 
Ampicillin stock solution : 100 mg/ml ampicillin sodium salt was dissolved in  
               H2O. 
Tetracycline stock solution:  25 mg/ml tetracycline was dissolved in 60% EtOH  
(v/v in H2O). 
Streptomycin stock-solution: 30 mg/ml streptomycin was suspended in H2O.  
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All antibiotics were stored in aliquots at -20°C and were added just before use, i.e. for 
agar plates right before pouring the plates at 50°C. 
 
2.3.1.2 SOC-medium 
SOC-medium (Sambrook et al., 1989) was used for culture of recombinant bacteria 
directly after their transformation. 
SOC-medium : 100 ml SOB-medium compl.; 10 mM MgCl2; 10 mM 
MgSO4; 20 mM glucose 
SOB-medium compl. : 20 g bacto-trypton; 5 g bacto-yeast extract; 0.5 g NaCl; 
H2O ad 1000 ml; autoclaved for sterilization, 20 ml 1M 
MgSO4 were added before use 
2.3.1.3 BHI-broth 
Brain Heart Infusion (BHI)-broth or BHI-agar plates (Difco, Detroit, MI) were used for 
culture of L. monocytogenes. 
2.3.2 Medium for cell culture 
2.3.2.1 IMDM complete 
Iscove´s modified Dulbecco´s modified Eagle´s medium (IMDM-medium, Gibco BRL, 
Eggenstein, Germany) is a complete powdered medium and was prepared according 
to manufacturer´s protocol. After addition of 10% FCS, 2 mM L-glutamin, 0.25 µM b-
mercaptoethanol (Serva, Heidelberg, Germany), 100 U/ml penicillin and 100 µg/ml 
streptomycin (Cytogen, Ober-Mörlen, Germany), IMDM complete medium was 
utilized as standard medium for tissue culture. 
FCS : Integro, Zaandam, The Netherlands; were heated up for 
30 min at 65°C to inactivate the complement system 
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2.4 Oligonucleotides  
All primers were ordered from GIBCO BRL. Nucleotides are listed in 5'-3'-direction. 
1 AmpR VORW EcoRI: GCGCGCGAATTCTTCAAATATGTATCCGCTCATGAG 
2 AmpR REV BKS:   AGATCTGGTACCACTAGTTTACCAATGCTTAATCAGTGA 
3 pUCori VORW SalI:  ATAAGAGTCGACAGGAACCGTAAAAAGGCCGCGTTG 
4 pUCori REV SKB:   ACTAGTGGTACCAGATCTGTAGAAAAGATCAAAGGATCT 
5 PTetR Vorw EcoRI:  ATAAGAGAATTCTCATGTTTGACAGCTTATCATCGATAA 
6 TetR Rev SpeI:   GCGCGCACTAGTTCAGGTCGAGGTGGCCCGGCT 
7 pMB1 Vorw SalI:   ATAAGAGTCGACTGGCATTGACCCTGAGTGATTTTTCTC 
8 p15Aori Vorw SalI:   GCGCGCGTCGACTCAGCGCTAGCGGAGTGTATA 
9 p15ori Rev BglII:   ATAAGAAGATCTTTAATAAGATGATCTTCTTGAGATCGTTTT 
10 pWSK29 Vorw SalI:  GCGCGCGTCGACGCAGACCCGCCATAAAACGCCCTG 
11 pSC101 Rev BglII:   ATAAGAAGATCTTCAGATCCTTCCGTATTTAGCCAGTAT 
12 PCmR Vorw PstI:   ATAAGACTGCAGTACCTGTGACGGAAGATCACTTCGCAG 
13 CmR Rev SpeI:   GCGCGCACTAGTTTACGCCCCGCCCTGCCACTCATC 
14 Seq1 pCMVßm:   GACCTGCAGGCATGCAAGCTC 
15 Seq2 pCMVßm:   AGATCTGGTACCACTAGT 
16 Seq3 pCMVßm:   ACTAGTGGTACCAGATCT 
17 Seq4 pCMVßm:   GGATCCTCTAGAGTCGAC 
* restriction sites are indicated in color 
*   
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2.5 Plasmids 
2.5.1 pCMVß 
The eukaryotic expression plasmid pCMVb (Clontech, Palo Alto, CA) is a reporter 
plasmid for the expression of ß-galactosidase in mammalian cells driven by the 
human cytomegalovirus immediate early promoter (P CMV IE). It contains a splice 
donor/splice acceptor site (SV40 SD/SA) and polyadenylation signal from SV40 
(SV40 polyA) as well as the full-length E. coli gene lacZ with eukaryotic translation 
initiation signals for expression of ß-galactosidase (ß-Gal). Further, it includes an 
ampicillin resistance marker (AmpR) and the origin of replication from pUC (pUCori). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.2 pEF1ß 
Since it was reported that the CMV IE promoter could be down-regulated by IFNg 
(Qin et al., 1997), which is strongly induced after immunization with S. typhimurium 
pCMVß
7164 bp
ß-Gal
SV40 polyA
SV40 SD/SA     .
CMV IE
pUCori
AmpR
Cla I (1781)
Eco RI (2)
Hin dIII (4531)
Sal I (4513)
Sma I (833)
Xho I (641)
Not I (820)
Not I (4294)
Pst I (24)
Pst I (4523)
Sac II (820)
Sac II (4300)
Xba I (625)
Xba I (4507)
Bam HI (631)
Bam HI (709)
Bam HI (4303)
Bam HI (4501)
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aroA- for host defense, a series of plasmids was constructed that contain different 
kind of promoters to avoid this problem. 
pEF1ß is a plasmid for eukaryotic expression of ß-galactosidase under the human 
elongation factor 1a promoter (Uetsuki et al., 1989; Kim et al., 1990) on the backbone 
of pCMVß (Garbe, A.I., Braunschweig). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.3 pUbiß 
 
 
 
 
 
 
 
 
 
 
 
 
pUbiß
7749 bp
ß-Gal
SV40 polyA
SV40 SD/SA     .
Ubi
pUCori
AmpR
Cla I (2366)
Eco RI (2)
Hin dIII (5116)
Pst I (5108)
Sal I (5098)
Sma I (1418)
Spe I (1165)
Xba I (5092)
Not I (1405)
Not I (4879)
Sac II (35)
Sac II (1405)
Sac II (4885)
Bam HI (1294)
Bam HI (4888)
Bam HI (5086)
pEF1ß
7714 bp
ß-Galactosidase
EF1-alpha
pUC ori
AmpR
Cla I (2331)
Eco RI (2)
Pst I (5073)
Sma I (1383)
Sal I (5063)
Xho I (1187)
Xba I (5057)
Hin dIII (8)
Hin dIII (5081)
Not I (1370)
Not I (4844)
Bam HI (1259)
Bam HI (4853)
Bam HI (5051)
Sac II (273)
Sac II (604)
Sac II (1370)
Sac II (4850)
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Expression plasmid for ß-galactosidase driven by the human ubiquitin promoter 
(Nenoi et al., 1996) on the backbone of pCMVß (Garbe, A.I., Braunschweig). 
2.5.4 pIRF-1ß 
Plasmid for eukaryotic expression of ß-galactosidase driven by the human interferon 
regulatory factor-1 (IRF-1) promoter (Sims et al., 1993) on the backbone of pCMVß 
(Garbe, A.I., Braunschweig). The IRF-1 promoter should be up-regulated by IFNg that 
is induced due to immunreactions of the host. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.5 pDCAß 
Expression plasmid for ß-galactosidase (Garbe, A.I., Braunschweig) under the 
CD11c-ß-globin promoter (CD11c promoter) on the backbone of pBSCD11c (kindly 
provided by T. Brocker). 
 
 
pIRF-1ß
6948 bp
ß-Gal
SV40 polyA
SV40 SD/SA     .
IRF-1
pUCori
AmpR
Cla I (1565)
Eco RI (2)
Hin dIII (4315)
Pst I (4307)
Sal I (4297)
Xba I (4291)
Not I (604)
Not I (4078)
Sac II (202)
Sac II (604)
Sac II (4084)
Sma I (139)
Sma I (210)
Sma I (617)
Bam HI (493)
Bam HI (4087)
Bam HI (4285)
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2.5.6 phLPß 
Expression plasmid for ß-galactosidase driven by the human lysozyme promoter 
(hLP) (Dighe et al., 1995; Clarke et al., 1996) on the backbone of pCMVß (Garbe, 
A.I., Braunschweig). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pDCAß
12811 bp
lacZ
ß-galactosidase
CD11c promoter      .
ColE1 origin
f1 (+) origin
AmpR
~ 12,8 kb 
phlpß
10000 bp
ß-Gal
SV40 polyA
SV40 SD/SA     .
hLP
pUCori
XHO I (3476)
AmpR
Eco RI (2)
Not I (3656)
Not I (7130)
~ 1  kb 
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2.5.7 pCMVßm1A 
For the cloning of the eukaryotic expression plasmids with different origins of 
replication and the possibilty to exchange the antibiotic resistance, the eukaryotic 
expression plasmid pCMVß (Clontech, Palo Alto, CA) was reconstructed to introduce 
unique restriction enzyme sites resulting in pCMVßm1A. 
The pCMVß was digested with EcoRI and SalI to remove the pUCori and the 
ampicillin resistance gene. The pUCori was then amplified by PCR using primers 
pUCori VORW SalI and pUCori REV SKB providing restriction enzyme sites SalI 5´ 
and SpeI, KpnI and BglII 3´ of the ori. For the ampicillin resistance gene the primers 
AmpR VORW EcoRI and AmpR REV BKS were used to introduce 5´ BglII, KpnI and 
SpeI and 3´EcoRI. Both overlaying fragments were joined together by amplification in 
a second PCR. Finally, the fragment pUCori-AmpR was ligated via EcoRI and SalI 
with the pCMVß fragment carrying the lacZ gene under the control of the CMV 
promotor to give pCMVßm1A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.8 pCMVßm2A 
The low copy number pMB1replicon from pBR322 (Sutcliffe,J.G.,1979), containing 
the pUCori and the rop gene from the ColE1 derivative pMB1, was amplified by PCR 
pCMVßm1A
6110 bp
ß-Galactosidase        .
pUCori
SV40 polyA
SV40 SD/SA
CMV IEAmpR
Cla I (1781)
Eco RI (2)
Pst I (24)
Sal I (4513)
Sma I (833)
Kpn I (5173)
Spe I (5175)
Bgl II (5163) Xho I (641)
Not I (820)
Not I (4294)
Sac II (820)
Sac II (4300)
Xba I (625)
Xba I (4507)
Bam HI (631)
Bam HI (709)
Bam HI (4303)
Bam HI (4501)
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with the primers pMB1 Vorw SalI and pUCori REV SKB. After digestion with 
BglII/SalI, the pMB1replicon was inserted in pCMVßm1A, creating pCMVßm2A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.9 pCMVßm3A 
 
 
 
 
 
 
 
 
 
 
 
 
 
pCMVßm2A
6880 bp
ß-Galactosidase       .
pMB1ori
SV 40 poly A
SV 40 SD/SA
CMV IE
AmpR
Bgl II (5933)
Cla I (1781)
Eco RI (2)
Kpn I (5943)
Pst I (24)
Sal I (4513)
Sma I (833)
Spe I (5945)
Xho I (641)
Not I (820)
Not I (4294)
Sac II (820)
Sac II (4300)
Xba I (625)
Xba I (4507)
Bam HI (631)
Bam HI (709)
Bam HI (4303)
Bam HI (4501)
pCMVßm3A
6299 bp
ß-Galactosidase
p15A ori
SV 40 poly A
SV 40 SD/SA    .
CMV IEAmpR
Bgl II (5352)
Cla I (1781)
Eco RI (2)
Kpn I (5362)
Pst I (24)
Sal I (4513)
Sma I (833)
Spe I (5364)
Xho I (641)
Not I (820)
Not I (4294)
Xba I (625)
Xba I (4507) Sac II (820)
Sac II (4300)
Sac II (4776)
Bam HI (631)
Bam HI (709)
Bam HI (4303)
Bam HI (4501)
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pCMVßm3A was constructed by cloning the PCR-amplified low copy number p15Aori 
from pACYC 184 (Chang and Cohen, 1978) with primers p15Aori Vorw SalI and 
p15Aori Rev BglII in pCMVßm1A. pACYC184 is a low copy number cloning vector 
that carries the ori from p15A. Plasmids carrying this origin of replication can co-exist 
with vectors carrying the ColE1 origin such as pBR322 or pUC19. 
2.5.10 pCMVm4A 
For construction of plasmid pCMVßm4A, PCR amplification of the very low copy 
number pSC101ori was performed using pWSK29 (Wang and Kushner, 1991) as a 
template with pWSK29 Vorw SalI and pSC101 Rev BglII and cloned into pCMVßm1A 
after digestion with BglII/SalI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.11 pCMVm2T 
To insert the tetracycline resistance gene instead of the ampicillin cassette in 
pCMVßm2T the TetR gene was PCR amplified with PTetR Vorw EcoRI and TetR 
Rev SpeI and ligated via EcoRI/SpeI into pCMVßm2A that removed the ampicillin 
resistance at the same time.  
pCMVßm4A
7011 bp
ß-Galactosidase     .
pSC101ori
SV 40 poly A
SV 40 SD/SA
CMV IE
AmpR
Bgl II (6064)
Cla I (1781)
Eco RI (2)
Kpn I (6074)
Pst I (24)
Sal I (4513)
Sma I (833)
Xho I (641)
Not I (820)
Not I (4294)
Sac II (820)
Sac II (4300)
Spe I (5041)
Spe I (6076)
Xba I (625)
Xba I (4507)
Bam HI (631)
Bam HI (709)
Bam HI (4303)
Bam HI (4501)
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2.5.12 pCMVßm3T 
For cloning of pCMVßm3T, the amplified TetR gene (see 2.5.11) was introduced into 
pCMVßm3A via EcoRI and SpeI similar to pCMVßm2T. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pCMVßm2T
7222 bp
ß-Galactosidase     .
pMB1 replicon
SV 40 poly A
SV 40 SD/SA
CMV IE
TetR
Bgl II (5932)
Eco RI (1)
Hin dIII  (7192)
Kpn I (5942)
Pst I (23)
Sma I (832)
Spe I (5944)
Xho I (640)
Cla I (7199)
Cla I (1780)
Not I (819)
Not I (4293)
Sac II (819)
Sac II (4299)
Sal I (6570)
Sal I (4512)
Xba I (624)
Xba I (4506)
Bam HI (630)
Bam HI (708)
Bam HI (4302)
Bam HI (4500)
Bam HI (6846)
pCMVßm3T
6641 bp
ß-Galactosidase    .
p15A ori
SV40 poly A
SV40 SD/SA
CMV IE
TetR
Bgl II (5352)
Eco RI (2)
Hin dIII (6612)
Kpn I (5362)
Pst I (24)
Sma I (833)
Spe I (5364) Xho I (641)
Cla I (6619)
Cla I (1781)
Not I (820)
Not I (4294)
Sal I (5990)
Sal I (4513)
Xba I (625)
Xba I (4507)
Sac II (820)
Sac II (4300)
Sac II (4776)
Bam HI (6266)
Bam HI (631)
Bam HI (709)
Bam HI (4303)
Bam HI (4501)
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2.5.13 pCMVßm4T 
pCMVßm4T was constructed by exchange of AmpR in pCMVßm4A against TetR 
from pCMVßm2T after digestion with EcoRI and BglII. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.14 pCMVßm3C 
 
 
 
 
 
 
 
 
 
 
 
 
pCMVßm4T
7353 bp
ß-Galactosidase    .
pSC101ori
SV40 polyA
SV40 SD/SA
CMV IE
TetR
Bgl II (6064)
Eco RI (2)
Hin dIII (7324)
Kpn I (6074)
Pst I (24)
Sma I (833)
Xho I (641)
Cla I (7331)
Cla I (1781)
Not I (820)
Not I (4294)
Sac II (820)
Sac II (4300)
Sal I (6702)
Sal I (4513)
Spe I (5041)
Spe I (6076)
Xba I (625)
Xba I (4507)
Bam HI (631)
Bam HI (709)
Bam HI (4303)
Bam HI (4501)
Bam HI (6978)
pCMVßm3C
6210 bp
ß-Galactosidase
p15A ori
SV 40 poly A
SV 40 SD/SA    .
CMV IECmR
Bgl II (5334)
Cla I (1763)
Eco RI (5793)
Kpn I (5344)
Pst I (6)
Sal I (4495)
Sma I (815)
Spe I (5346)
Xho I (623)
Not I (802)
Not I (4276)
Xba I (607)
Xba I (4489) Sac II (802)
Sac II (4282)
Sac II (4758)
Bam HI (613)
Bam HI (691)
Bam HI (4285)
Bam HI (4483)
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The chloramphenicol resistance gene (CmR) was amplified from plasmid pACYC184 
by PCR using the primers PCmR Vorw PstI and CmR Rev SpeI and was introduced 
into pCMVßm3A by digestion and ligation with the restriction endonucleases PstI and 
SpeI. 
2.5.15 pCMVhly 
The plasmid pCMVhly (Darji et al., 1997) contains a fragment of the hly gene from  
L. monocytogenes encoding a non-hemolytic variant of listeriolysin as antigen. This 
plasmid was used for protection studies against infection with L. monocytogenes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.16 pCMVhlym2A 
The hly gene was excised from pCMVhly with NotI and inserted into pCMVßm2A by 
replacing lacZ, thus giving pCMVhlym2A. pCMhlym2A was used as a low copy 
number vector in protection studies. 
pCMVhly
5076 bp
hly
SV40 polyA
SV40 SD/SA     .
CMV IE
pUCori
AmpR
Sal I (2425)
Xho I (641)
Cla I (937)
Cla I (2017)
Eco RI (2)
Eco RI (1154)
Not I (820)
Not I (2206)
Pst I (24)
Pst I (2435)
Sac II (820)
Sac II (2212)
Xba I (625)
Xba I (2419)
Hin dIII (1339)
Hin dIII (1990)
Hin dIII (2443)
Bam HI (631)
Bam HI (709)
Bam HI (2215)
Bam HI (2413)
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2.6 Antibodies 
anti-ß-galactosidase : monoclonal IgG2a; purified from ascites of a mouse   
   hybridoma; recognizes E. coli ß-galactosidase; Conc.: 
   2 mg/ml (Promega, Mannheim, Germany) 
goat-anti-mouse IgG (h+l) : polyclonal; peroxidase conjugated; conc.: 0,8 mg/ml  
   (Dianova, Hamburg, Germany) 
rat-anti-mouse IFNg : monoclonal IgG1; clone R4-6A2; conc.: 1 mg/ml  
    (Pharmingen, San Diego, CA) 
rat-anti-mouse IFNg : monoclonal IgG1; clone XMG1.2; biotinylated; conc.:  
   0.5 mg/ml (Pharmingen, San Diego, CA) 
pCMVhlym2A
4792 bp
hly
pMB1ori
SV 40 poly A
SV 40 SD/SA       .
CMV IE
AmpR
Bgl II (3845)
Kpn I (3855)
Pst I (24)
Sal I (2425)
Spe I (3857)
Xho I (641)
Cla I (937)
Cla I (2017)
Eco RI (2)
Eco RI (1154)
Hin dIII (1339)
Hin dIII (1990)
Not I (820)
Not I (2206)
Sac II (820)
Sac II (2212)
Xba I (625)
Xba I (2419)
Bam HI (631)
Bam HI (709)
Bam HI (2215)
Bam HI (2413)
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2.7 Antigens 
2.7.1 b-Galactosidase 
The b-galactosidase protein (Boehringer, Mannheim, Germany) was used as antigen 
in cellular assays and ELISA. The synthetic peptide aa 877-885: TPHPARIGL  
(H-2kd) was utilized for BALB/c mice in ELISPOT and the JAM-assay. 
2.7.2 Listeriolysin 
Purified, hemolytically active listeriolysin (LLO) (Darji et al., 1995) was used in 
proliferation assays. The LLO peptide aa 91-99: GYKDGNEYI (H-2kd) (Pamer et al., 
1991) was used for ELISPOT. 
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3 Methods 
3.1 Molecular biological methods 
3.1.1 Agarose gel electrophoresis 
The agarose gel electrophoresis was applied for separation of linearized, double-
stranded DNA fragments. The separation depends on the migration of DNA 
fragments in an electric field due to their molecular size. Because of that the size of 
the DNA fragments can be estimated by comparison with marker DNA comprising 
molecules of known size. This method was employed for analytical as well as for 
preparative purposes. In this study, gels were used at concentrations of 0.8 % (w/v) 
agarose (Appligene, Heidelberg, Germany) in TAE buffer and run at 120-140 V. DNA 
fragments became visible with UV light after staining with ethidium bromide and were 
documented photographically after sufficient separation. 
TAE-buffer : according to Sambrook et al., 1989 
Marker-DNA : mix of HindIII-digested l-DNA and HaeIII-digested 
pFX174-DNA (MBI-Fermentas, St. Leon-Rot, Germany) 
Electrophoresis-system: Horizon 11.14 (Gibco BRL Eggenstein, Germany) 
3.1.1.1 Isolation of DNA from agarose gels 
The DNA fragment of interest was carefully cut out from the gel. Subsequently, the 
DNA was extracted from the gel using the „QIAquick Gel Extraction Kit“ (Qiagen, 
Hilden, Germany) according to manufacturer’s protocols. DNA was always eluted in 
50 µl water and stored at –20°C until use. 
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3.1.2 Isolation of Plasmid-DNA 
Depending on the required amount of plasmid DNA, mini or maxi plasmid 
preparations were performed to isolate DNA from bacteria. To purify plasmid DNA 
from E. coli strains, the “GFX Micro Plasmid Prep Kit” (Amersham Biosciences, 
Freiberg, Germany) was used for analytical and the "Qiagen Plasmid Maxi Kit“ 
(Qiagen, Hilden, Germany) for preparative purposes. The “Qiagen Plasmid Mini Kit” 
(Qiagen, Hilden, Germany) was employed for purification of plasmid DNA from 
Salmonella strains.  
3.1.3 Determination of DNA concentration 
3.1.3.1 Optical determination 
For optical determination of the DNA concentration, the extinction of a sample was 
measured at 260 nm. The OD260 of 1 corresponds (at a diameter of the cuvette of 1 
cm) to a DNA concentration of 50 µg/ml.  
Photometer : BioPhotometer (Eppendorf, Hamburg, Germany) 
3.1.3.2 Visual comparison with marker DNA 
This method only permits the determination of concentration from linearized DNA. 
Thereby, DNA fragments can be quantitated by running a sample alongside marker 
DNA that contains defined quantities and sizes of DNA fragments. The amount of 
sample DNA loaded can be estimated by visual comparison of the band intensity with 
that of the marker DNA.  
3.1.4 Molecular Cloning 
Molecular cloning comprises the cleavage of plasmid DNA with restriction enzymes 
and joining to foreign DNA fragments by the use of ligase. Thereby, fragments of 
foreign DNA and vector DNA carrying noncomplementary protruding termini, identical 
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protruding or blunt-ended termini can be covalently linked. The resulting recombinant 
plasmids are then used to transform bacteria.  
3.1.4.1 Digestion of DNA with restriction enzymes 
Plasmids and PCR products were digested with appropriate restriction endo-
nucleases for analysis and preparation of defined linear DNA strands. Digestion of 
DNA was carried out using optimal buffer and temperature conditions for each 
enzyme according to manufacturer’s protocol. Finally, an aliquot of the digestion mix 
was analyzed by agarose gel electrophoresis for completion of digestion. 
3.1.4.2 Ligation of DNA 
Ligation of a foreign DNA fragment to a linearized plasmid vector involves the 
formation of phosphodiester bonds. In this study, T4 DNA ligase (Gibco BRL, 
Eggenstein, Germany) was used to catalyze the formation of a phosphodiester bond 
between juxtaposed 5´phosphate and 3´hydroxyl termini in duplex DNA. 
Recircularization of vector DNA can be limited by adding a higher concentration of 
foreign DNA than of the plasmid vector in the ligation reaction. Therefore, vector and 
fragment, which were previously digested with the same or compatible restriction 
enzymes, were ligated in a molar ratio of 1:10 and incubated at room temperature for 
30-60 minutes.  
Reaction mix : <50 ng vector DNA 
  <500 ng DNA fragment 
  1 U T4 DNA ligase 
  1x ligase buffer 
  H20 ad 20 µl 
5x ligase buffer : (Gibco BRL, Eggenstein, Germany) 
3.1.4.3 Fill-in of restriction endonuclease ends 
To ligate two DNA strands without compatible restriction sites, overhanging DNA 
ends were modified to form blunt ends using T4 DNA Polymerase (New England 
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Biolabs, Frankfurt am Main, Germany). This enzyme catalyzes the synthesis of DNA 
in the 5’ ® 3’ direction to fill-in 5’ overhangs and has a 3’ ® 5’ exonuclease activity 
removing 3’ overhangs to form blunt ends.  
The fill-in reaction was incubated 15 min at 12°C, stopped by adding final 10 mM 
EDTA and heated for 20 min at 75°C. 
Reaction mix:  1-2 µg DNA with protruding "sticky end" 
  1x T4 DNA polymerase reaction buffer  
  0.2 mM nucleotides 
  1 U T4 DNA polymerase 
  H2O ad 100 µl 
T4 DNA polymerase  
reaction buffer (10x):   50 mM NaCl 
   10 mM Tris-HCl 
   10 mM MgCl2 
   1 mM dithiothreitol 
3.1.5 Transformation of bacteria 
Different methods of transformation were carried out to introduce plasmid DNA into 
bacteria. Therefore, appropriate competent cells have been prepared for 
transformation. 
3.1.5.1 Preparation of electrocompetent cells from S. typhimurium 
One liter of pre-warmed LB-broth (37°C) was inoculated with 10 ml of a fresh 
overnight culture. Bacteria were cultured at 180 rpm and 37°C until an optical density 
(OD600) of 0.5-1 was reached. After cooling the bacterial culture (15-30 min on ice), 
the bacteria were harvested by centrifugation for 15 min at 4000x g and 4°C. The 
pellet was washed once with 1l ice-cold H2O, afterwards with 500 ml ice-cold H2O 
and finally with 20 ml ice-cold glycerin (10% v/v in H2O). At the end, the bacterial 
pellet was resuspended in 2-3 ml ice-cold glycerin (10%) and aliquots (50 µl per lot) 
were stored at –70° until use. 
3 Methods 59 
 
3.1.5.2 Electroporation of S. typhimurium 
S. typhimurium strains were transformed by electroporation of competent cells. 
Before electroporation, the plasmid DNA was dialyzed against water for 20 min. For 
transformation, 1µg of DNA was added to 50 µl of competent bacteria and the 
suspension transferred into an ice-cold cuvette (2mm gap; BioRad, Munich, 
Germany). Electroporation parameters were 25 µF, 2.5 kV and 200 W (Gene Pulser 
II; BioRad, Munich, Germany). Subsequently, 1 ml SOC-medium was added to the 
cuvette and mixed. The suspension was transferred into an Eppendorf reaction tube, 
shaken for 1h at 37°C before plating on LB-agar plates containing the appropriate 
antibiotics. Plates were then incubated overnight at 37°C. 
3.1.5.3 Preparation of PEG-competent cells of E. coli strains 
5 ml LB-broth were inoculated with E. coli TOP 10 and incubated overnight at 37°C 
with agitation at 180 rpm. On the next day, 100 ml LB-broth were inoculated with 1 ml 
of the fresh overnight culture and grown at an OD600 of 0.6-0,65. The bacteria were 
cooled for 10 min on ice, harvested by centrifugation at 1500x g for 10 min and at 
4°C. The pellet was resuspended in 1 ml ice-cold solution A, 5 ml solution B was 
added and the suspension carefully mixed. Aliquots (100µl per lot) were stored at  
–70°C. 
Solution A : 10 mM MgSO4 
  0.2% glucose 
  in LB-broth, sterilization by filtration 
Solution B : 36% Glycerin 
  12% PEG 8000 (polyethylene glycol) 
  12 mM MgSO4 
  in LB-broth, sterilization by filtration 
3.1.5.4 PEG-transformation of E. coli strains 
100 µl of the PEG-competent cells were thawed on ice, mixed with 10 µl of a ligation 
reaction or 1µl of plasmid DNA and incubated for 30 min on ice. The bacteria were 
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then incubated for 1 min at 42°C and additionally 5 min on ice. 500 µl SOC-medium 
was added to the bacteria and the suspension was shaken for 30-45 min at 37°C. 
Finally, the bacterial suspension was plated on LB-agar plates containing selective 
antibiotics and incubated overnight at 37°C. 
3.1.6 Bacterial cultures 
Bacteria were grown on agar plates or in broth at 37°C. Liquid cultures of E. coli and 
L. monocytogenes were shaken at 180 rpm whereas recombinant Salmonella for oral 
genetic vaccination were cultured at 37°C and 50 rpm in LB-broth containing 1.5% 
NaCl (final) and supplemented with appropriate antibiotics when required. 
3.1.7 Long-term storage of bacteria 
To store bacteria for a long-term period, 700 µl of a fresh overnight culture was mixed 
with 300 µl glycerin (50% v/v in H2O) and frozen at -70°C.  
3.1.8 Polymerase chain reaction (PCR) 
PCR (Mullis, 1986) offers the possibility to detect small amounts of specific DNA. The 
principle of PCR is based on the enzymatic amplification of a DNA segment between 
two regions of known sequence. Two oligonucleotides are used as primers, which 
bind to complementary DNA strands in opposite directions and flank the DNA 
segment that is to be amplified. Amplification occurs in a series of synthetic reactions 
that are catalyzed by a DNA polymerase. First, the double stranded template DNA is 
denatured by heating at 95°C. Then, the complementary oligonucleotide primers, 
which are present in excess, are annealed to the single stranded DNA under 
hybridization conditions (at ca. 50-70°C). Subsequently, the DNA dependent, heat-
resistant DNA polymerase synthesizes complementary DNA sequences by extension 
of 3’-OH prime ends with nucleotides. Afterwards, the cycle of denaturation, 
annealing and extension is repeated several times. The specific DNA sequence can 
be amplified exponentially up to the factor 105-107 within 20 to 30 cycles  
In this study, the AmpliTaq Gold™ (Perkin Elmer, Weiterstedt, Germany) or the 
Cloned Pfu DNA Polymerase (Stratagene, Heidelberg, Germany) were used as 
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polymerase for PCR. The AmpliTaq Gold™-Polymerase is a thermostable DNA 
polymerase derived from Thermus aquaticus that is supplied in an inactive form and 
was activated by incubation for 10 min at 95°C at the beginning of the PCR-program. 
This avoids unwanted by-products due to unspecific annealing of oligonucleotides 
and polymerase activity at lower temperatures. 
The cloned Pfu DNA polymerase is isolated from the hyperthermophilic, marine 
archaebacterium Pyrococcus furiosus. The temperature optimum is at 72-78°C. 
Compared to the Taq-polymerase, the Pfu-polymerase possess 3’ to 5’ exonuclease 
proofreading activity that provides a 12x lower error rate in DNA synthesis than the 
Taq-polymerase. 
The thermocycler PCRExpress (Hybaid, MWG, Ebersberg, Germany) was used for 
DNA synthesis. 
Reaction mix : 1x PCR buffer 
  200 µM nucleotide mix 
  5-10 pmol primer 1 
  5-10 pmol primer 2 
  2,5 U AmpliTaq Gold™ oder Cloned Pfu DNA Polymerase 
  <1 µg DNA 
  H2O ad 20 µl 
Nucleotide mix (2 mM) : 100 mM stock solution of dATP, dCTP, dGTP, dTTP 
(Pharmacia Biotech, USA) diluted in H2O (1:50)  
10x PCR buffer  
for Taq-polymerase : 100 mM Tris-HCl (pH 8.3); 500 mM KCl; 15 mM MgCl2;  
   0.01% (w/v) gelatin; 
10x PCR buffer 
for Pfu-polymerase : 200 mM Tris-HCl (pH 8,8); 100 mM KCl; 100 mM  
  (NH4)2SO4; 20 mM MgSO4; 1 % Triton X-100; 1 mg/ml 
  nuclease-free BSA (bovine serum albumin) 
Reaction tubes : 0.2 ml (Applied Biosystems, Hamburg, Germany) 
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PCR conditions 
Program polymerase denaturation annealing extension Cycles 
AmpR Pfu 94°C; 20 sec 45°C; 30 sec 72°C; 2 min 32 
pUCori Pfu 94°C; 20 sec 45°C; 30 sec 72°C; 2 min 32 
AmpR-pUCori Pfu 94°C; 20 sec 45°C; 30 sec 72°C; 2 min 32 
pMB1 replicon Pfu 95°C; 1 min 45°C; 30 sec 72°C; 4 min 35 
PTetR Pfu 95°C; 1 min 45°C; 30 sec 72°C; 4 min 35 
p15Aori Pfu 95°C; 20 sec 45°C; 30 sec 72°C; 2 min 32 
pSC101ori Taq 95°C; 1 min 60°C; 1 min 72°C; 1 min 30 
PCmR Taq 95°C; 1 min 55°C; 1 min 72°C; 1 min 35 
Purification of PCR products 
Products from a PCR reaction were purified using the "QIAquick PCR-Purification Kit" 
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
3.1.9 DNA Sequencing 
The “ABI PRISM™ BigDye Terminator Cycle Sequencing Kit” (Perkin-Elmer, 
Weiterstedt, Germany), based on the chain-termination method of Sanger et al. 
(1977), was used for sequencing of double-stranded DNA. In this method, the DNA 
sequence of interest is amplified by a heat-stable DNA polymerase using a specific 
primer, but extension is terminated by the introduction of base-specific, fluorescent 
dye-labeled dideoxynucleoside triphosphates. PCR products were examined using 
polyacrylamide gels to discriminate between single-stranded DNA chains differing in 
length by a single nucleotide. 
Reaction mix for PCR:  4 µl BIG Dye PREMIX; 1 µg DNA; 3.2 pmol primer; H2O 
ad 20 µl 
PCR-Programm:  96°C, 30 sec denaturation 
  52°C, 15 sec annealing 
  60°C, 4 min extension 
  25 cycles 
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Sequence assessment and statistical analysis 
Sequences were analyzed using SequencherTM 3.0 (Gene Codes Corporation, 
Michigan, USA).  
3.2 Immunochemical methods 
3.2.1 ELISA (enzyme-linked immunosorbent assay) 
ELISA represents a highly sensitive and specific method for the quantitative detection 
of secreted proteins such as antibodies or cytokines. In the sandwich ELISA, the 
highly purified capture antibody is noncovalently adsorbed (“coated”) onto plastic 
microwell plates due to hydrophobic interactions. In turn, the immobilized antibodies 
capture soluble antigen from samples applied to the plate. After removal of unbound 
material, the captured antigen will be detected by a secondary antibody. This 
detection antibody is conjugated to an enzyme, which catalytically converts a 
chromogenic substrate. The level of colored product can be measured 
spectrophotometrically using an ELISA reader at an appropriate wave length. 
96-well-microtiter plates (Maxisorb™ Immunoplatten, Nunc, Wiesbaden, Germany) 
were coated with 50 µl/well of 0.5 µg/ml purified protein in coating buffer overnight at 
4°C to bind the primary antibody to the carrier. The next day, plates were washed 3x 
with wash buffer using an ELISA-washer (Dynatech, Denkendorf, Germany) and 
blocked by adding 200 µl of 5% FCS in wash buffer for 1 h at 37°C to saturate free 
binding sites. After additional washing, 50 µl of serum was added at 1:1000 dilutions 
in wash buffer with 2.5% FCS and incubated for another 3 h at 37°C. Binding was 
revealed by using peroxidase-conjugated anti-mouse IgG and OPD as substrate. 
Color reaction was stopped by addition of 1 M sulfuric acid and measured with an 
ELISA reader MR 500 (Dynatech, Denkendorf, Germany) at 490 nm. 
Coating buffer : 0.1 M Na2CO3; 0.1 M NaHCO3; pH 9.6 in H2O 
Wash buffer : 0.1% Tween 20 in PBS (according to Sambrook et al.,  
                                1989) 
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OPD-substrate solution : 1 mg/ml O-phenylendiamine in substrate buffer, 1 µl/ml  
                                           H2O2 
Substrate buffer : 0.2 M NaH2PO4; 0.1 M Na3-Citrat; pH 5.0 
To evaluate the levels of specific antibodies against ß-galactosidase or listeriolysin, 
standard ELISA was employed with serum from immunized mice. 
 
detection of 1. antibody Sample 2. antibody 
mAb-b-Gal 0.5 µg/ml b-Gal Mouse serum goat-anti-mouse 
IgG (h+l) 
mAb-LLO 0.5 µg/ml wt-
LLO 
Mouse serum goat-anti-mouse 
IgG (h+l) 
3.2.2 ELISPOT (enzyme-linked immunospot assay) 
The solid-phase enzyme-linked immunospot assay presents a powerful technique for 
detecting and enumerating individual cells that secrete a particular protein in vitro. 
The ELISPOT assay is based on the sandwich ELISA and receives its specificity and 
sensitivity by applying high affinity capture and detection antibodies as well as 
enzyme amplification of the color reaction. The assay can be employed not only for 
analyzing specific antibody-secreting cells, but also for measuring the frequencies of 
cells producing and secreting other effector molecules like cytokines. In this study, 
the ELISPOT assay was utilized to determine and to evaluate antigen-specific, IFNg-
secreting CD8+ T cells from immunized mice. 
Before the MAHA plates (Millipore Multiscreen-HA 96-well filtration sterile plates, 
Millipore, Bedford, MA) were coated with 50 µl/well R4 monoclonal capture antibody 
(25 µg/ml), they were moistened with PBS. After incubation overnight at 4°C with the 
capture antibody, the plates were washed five times with 200 µl/well PBS and 
blocked by adding 100 µl/well of IMDM medium containing 10 % FCS for 2 h at room 
temperature (RT). In the meantime, the restimulated lymphocytes were washed five 
times with medium; the number of viable cells was determined and adjusted to  
2 x 106 cells/ml. From this cell suspension 50 µl/well were added to the ELISPOT 
plate after discarding the blocking solution. Then, 50 µl of peptide (2 µg/ml) in IMDM 
compl. were added per well for stimulation. The ß-galactosidase peptide aa877-885 
or LLO peptide aa91-99 were used as specific antigen (depending on the vector 
taken for immunization) and the respective other peptide as negative control in each 
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case. The plates were incubated for 24 h undisturbed at 37°C and 5% CO2. 
Afterwards, the cell suspension was removed and wells were washed three times 
with PBS, once with water (leaving water in wells for 5 min to lyse remaining cells) 
and then twice more with PBS. The biotin-conjugated rat-anti-mouse IFNg detection 
antibody was diluted 1:350 in PBS and 50 µl of antibody was put to each well. Plates 
were incubated at RT for 2 h or overnight at 4°C. Next, the plates were washed five 
times with PBS before adding 50 µl/well of streptavidine polyalkaline phosphatase 
(1:750; Sigma, Munich, Germany). After incubation for 2 h at RT, the wells were 
washed again five times with PBS and IFNg production was measured by adding 50 
µl/well substrate solution. Color development was allowed at RT and substrate 
reaction was stopped by washing wells five times with water. Before enumerating the 
spots manually by inspection under the microscope, the plates have to dry at least for 
1 h in the dark until the plates are completely dry. 
Substrate solution:  BioRad Conjugate Substrate Kit (BioRad, Munich,  
                     Germany) 
3.3 Tissue culture 
3.3.1 Culture conditions 
Mammalian cells were cultivated in IMDM medium at 37°C and 5% CO2 in a humified 
atmosphere. 
3.3.2 Determination of viable cells 
An aliquot of a cell suspension was diluted 1:1 with 0.5% (w/v) trypan blue in PBS 
and 10 µl of this mixture were put into a Neubauer chamber. The number of viable 
cells in a big square multiplied with the dilution factor 1 x 104 resulted in the cell 
number per milliliter. Only viable cells, whose plasma membrane compared to dead 
cells are not leaky for trypan blue and therefore are not stained, were considered. 
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3.3.3 Removal of adherent cells 
Adherent growing cells have to be detached from the culture dish for counting and 
transfer to new culture flasks. Therefore, cells were washed once with PBS, removed 
enzymatically from the substrate by adding trypsin-EDTA solution (TE) and incubated 
at 37°C in a humified atmosphere until the cells were detached. Immediately, TE was 
inactivated by addition of FCS containing medium. The cells were harvested by 
centrifugation, washed once with PBS and resuspended in medium 
PBS : 137 mM NaCl; 2.6 mM KCl; 6.4 mM Na2HPO4 x 2 H2O; 
1.4 mM KH2PO4; in H2O (pH 7) 
TE : 0.5 g/ml trypsin; 0.2 g/ml EDTA; in PBS 
3.3.4 Conservation of mammalian cells 
Cells from a dense growing 12- or 6-well plate were taken in 0.5 ml ice-cold freezing 
medium. The cell suspension was temporarily frozen at -70°C and finally stored in 
liquid nitrogen. 
Freezing medium : 10 % (v/v) dimethylsulfoxide (Merck, Darmstadt, Germany) 
in FCS 
3.3.5 Thawing of cells 
The frozen cells were thawed at 37°C in a water bath and the cell suspension was 
taken up in medium. Afterwards, the cells were harvested by centrifugation, washed 
once and resuspended in medium 
3.4 Calcium phosphate transfection 
Transfection represents a method for the transfer of DNA into cell culture cells. The 
principle of calcium phosphate–precipitation is based on the formation of an insoluble 
precipitate of calcium phosphate, to which the DNA can be adsorbed. These calcium 
phospate-DNA-complexes are taken up by the cells through endocytosis. The DNA 
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reaches the nucleus, where it can be transcribed (transient transfection). Some of the 
DNA can be integrated into the genome of the recipient cell (stable transfection), 
which can subsequently transmit this DNA segment to the next cell generation. 
Practically: 3 x 105 adherent cells per 25 cm2 culture flask were seeded the day 
before. The medium was exchanged for 5 ml of fresh medium 4 h before transfection. 
For preparation of the calcium phosphate/DNA coprecipitate, 250 µl of the CaCl2-
DNA-mixture were added drop by drop under gentle mixing to 250 µl HEBS-buffer 
(2x) and incubated for 30-60 min at room temperature. The precipitate was then 
added to the medium above the cells and the transfected cells were cultured at 37°C. 
Excess of precipitate was removed the next day by exchange of medium. 
HEBS-buffer (2x) : 280 mM NaCl; 50 mM HEPES; 1.5 mM Na2HPO4 x 2H2O; 
ad 100 ml; adjust with 5 M NaOH to pH 7,1; sterile 
filtering, aliquots stored at -20°C 
CaCl2-DNA-mixture : 25 µl CaCl2 (250 mM); 10 µg cotransfer-DNA; H2O ad  
250 µl 
3.5 Infection of cell lines with S. typhimurium aroA- 
The day before infection with recombinant S. typhimurium, HEp-2 cells were seeded 
in 24-well plates at a density of 5x104 cells/well in IMDM medium without antibiotics. 
The recombinant Salmonella were grown overnight in LB broth containing 1.5% NaCl 
final at 37°C and 50 rpm up to an OD600 of ~0.8. Then, the bacteria were washed 
once with PBS and resuspended in antibiotic-free IMDM medium. After 24 h the HEp-
2 cells has reached a density of approximately 1x105 cells/well and were infected 
with an MOI (multiplicity of infection) of 200:1, 100:1 and 50:1 in a total volume of 200 
µl. The MOI was confirmed by plating serial dilutions of the suspension on LB-agar 
plates. Cultures were centrifuged to enhance infection and incubated for 1-2 h at 
37°C. Cells were washed three times with PBS and cultured in medium 
supplemented with 100 µg/ml gentamicin (Biochrom AG, Berlin, Germany) for 1h to 
kill the remaining extracellular bacteria. Afterwards the medium was exchanged for 
IMDM compl. containing penicillin and streptomycin and supplemented with 
gentamicin to kill the intracellular and extracellular Salmonella, respectively.  
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3.5.1 Determination of intracellular bacterial numbers 
In a parallel experiment, HEp-2 cells were infected as described above. One hour 
after incubation in gentamicin-containing medium, cells were washed three times with 
PBS and lysed for 30 min in 0.2% Triton-X 100 in H2O. Colony forming units of 
lysates were enumerated by plating serial dilutions. 
3.5.2 Detection of ß-galacosidase by in situ staining of cells 
Expression of ß-galactosidase could be visualized in fixed cells after cleavage of the 
indicator substrate X-gal (5-brom-4-chlor-3-indolyl-ß-D-galactopyranosid). HEp-2 
cells infected with recombinant Salmonella (see 3.5) were stained for ß-gal activity 
after 24 h and 48 h. The adherent cells were washed three times with PBS and air-
dried for 30 min at room temperature. Afterwards cells were fixed with ice-cold 
acetone/methanol (1:1 v/v) for 5 minutes. The fixing solution was aspirated and the 
cells dried again before adding the freshly prepared X-gal substrate. Color reaction 
was developed by incubation overnight at 37°C in a humified atmosphere and ß-gal-
expressing cells were detected due to their blue color by light microscopy. 
X-gal substrate:  K3FeIII(CN)6   5 mM   (stock solution: 500 mM) 
K4FeII(CN)6    5 mM   (stock solution: 500 mM) 
MgCl2              2 mM   (stock solution: 500 mM) 
X-gal        100 µg/ml   (stock solution: 10 mg/ml) 
Stock solutions were stored at -20°C. 
3.6 Immunization with recombinant Salmonella 
3.6.1 In vitro plasmid stability 
All S. typhimurium strains were cultured in LB-broth containing 1.5 % NaCl overnight 
at 37°C at 50 rpm until they reach OD600 of 0.8 and passaged for 5 days in cultures 
with or without antibiotic selection. The percentage of stability was calculated by 
counting colony forming units (cfu) on antibiotic agar plates divided by total viable cfu 
on LB agar without selecting antibiotics, multiplied with 100. 
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3.6.2 Colonization and in vivo plasmid stability 
At different time points after a single oral immunization with the recombinant 
Salmonella (see 3.6.3), Peyer´s patches, mesenteric lymph nodes, spleen and liver 
were removed. Organs were homogenized in 1 ml 0.1% Triton X-100 at 10000 rpm 
using a homogenizer (Polytron PT 3000, Kinematica AG, Littau-Lucerne, 
Switzerland) to lyse the cells in the suspension. Serial dilutions were plated on LB- 
Agar with or without antibiotics and the cfu were determined after overnight 
incubation at 37°C to assess bacterial colonization and the percentage of plasmid 
stability. 
3.6.3 Oral Immunization 
For in vivo studies, S. typhimurium aroA- were grown in LB-broth containing 1.5% 
NaCl (final) at 50 rpm and 37°C overnight until they have reached an OD600 of 0.8. It 
was assumed that at an OD600 of 0.8 1ml of culture contains approximately 5x 108 
bacteria. After the bacteria were washed 2x in PBS, they were resuspended in 
sodiumbicarbonate (5% w/v in PBS). The number of bacteria in solution was adjusted 
to 1-5 x 108 per 100 µl by measuring the optical density (OD600) and was confirmed 
by plating serial dilutions of the suspension. Groups of mice were inoculated with  
1-5 x 108 recombinant Salmonella intragastrically using a gavage needle (Acufirm 
#1428LL, Dreieich, Germany). 
Mice received either a single or four doses of recombinant Salmonella in 21-30 day 
intervals and the induction of cellular immune responses were analyzed in spleen 
and lymphnode. To examine the induction of specific cytotoxic CD8+ T cells, the 
JAM-assay or ELISPOT for IFNg production was performed. CD4 T cell proliferation 
was measured by a helper-T-cell assay using the WST method. To investigate 
humoral responses, the serum of mice was analyzed for antigen specific antibodies 
in ELISA.  
3.6.4 Preparation and analysis of mouse serum 
At different time points, mice were bleed from the tail vein or blood was taken from 
the heart after the mice had been sacrificed. To separate serum from the blood clot, 
the blood was centrifuged for 10 min at maximal speed in an Eppendorf centrifuge. 
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The serum was then stored at-20°C until it was investigated for antigen specific 
antibodies by ELISA. 
3.6.5 Preparation and culture of T cells 
At different time points after immunization, mice were sacrificed and spleen, Peyer´s 
patches and mesenteric lymphnodes were isolated under aseptic conditions. Splenic 
T cells were isolated by washing out the spleen with 10 ml erythrocyte-lysis-buffer, 
centrifuged, washed once with IMDM complete and resuspended in the same 
medium. T cell were also prepared through gentle homogenization of mesenteric 
lymphnodes, washed and taken up in medium.  
One part of the cells was used for proliferation assays and the JAM-assay ex vivo. 
The other part was cultivated in medium sized culture flasks with 15-20 ml medium 
for 5 days to use them after specific restimulation for ELISPOT. 
Erythrocyte-lysis-buffer : 17 mM Tris; first dissolve in 800 ml H2O (pH 7.6); add 140 
mM NH4Cl; and H2O ad 1l; pH 7.2 
 
3.6.6 Helper-T-cell assay 
Isolated CD4+ T cells from immunized mice proliferate after addition of specific 
antigen in vitro. This cell proliferation and cell viability could be quantified by a 
colorimetric assay based on the cleavage of the tetrazolium salt WST-1 (Roche, 
Penzberg, Germany). WST-1 is cleaved to formazan by mitochondrial 
dehydrogenases in viable cells. An expansion of viable cells results in an increase in 
the overall activity of these enzymes and subsequently leads to an increase in the 
amount of formazan dye formed. This is directly correlated to the number of 
metabolically active cells in the culture. The production of the formazan dye could be 
quantified by an ELISA reader by measuring the absorbance of the dye solution at an 
appropriate wavelength. 
To carry out the cell proliferation assay after immunization, 6 x 105 isolated 
lymphocytes from spleen and mesenteric lymphnodes per well were incubated in 96-
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well-flat bottom tissue culture plates. The T cells were restimulated with 1-10 µg/ml of 
antigen in a final volume of 200 µl. After incubation of the plates for 24 h in a humified 
atmosphere, 20 µl/well cell proliferation reagent WST-1 was added and incubated for 
another 4 h at 37°C and 5% CO2. Then the plates were shaken thoroughly for 1 min 
on a shaker. The absorbance of the samples against a background control as blank 
was finally measured using an ELISA reader at 480 nm. 
3.6.7 Cytotoxic T cell assay 
To evaluate the induction of specific cytotoxic T cells after oral immunization, the 
JAM-assay was performed to directly measure cytotoxic activity of CD8+ T cells or 
the ELISPOT assay to determine the frequency of IFNg-secreting CD8+ T cells in 
response to specific antigenic peptide. 
Isolated lymphocytes from immunized animals were directly used in the JAM-assay. 
For ELISPOT assays, lymphocytes were restimulated in vitro for five days with  
1 µg/ml specific antigen in IMDM compl. in culture flasks at 37°C and 5% CO2. 
Therefore, cell cultures from individuals immunized with a ß-galactosidase 
expressing construct were restimulated with the ß-gal peptide and analogous 
listeriolysin primed cells with the CD8+-specific LLO peptide. After restimulation, the 
cells were harvested by centrifugation and analyzed by ELISPOT assay (see 3.2.2). 
3.6.8 JAM-assay 
The so-called JAM-assay (Matzinger, 1991) is a simple assay to measure DNA 
fragmentation and cell death to directly assess cytolytic activity. Proliferating target 
cells are labeled with [3H]thymidine by addition of [3H]thymidine into IMDM medium 
compl.. The radioactive thymidine is taken up by the cells and incorporated into the 
DNA during replication. Cytotoxic T cells can lyse these labeled target cells that 
release their DNA. Subsequently, free DNA is degraded into small fragments. After 
incubation of target cells with CTLs, cells were harvested by vacuum aspiration 
through fiberglass filters at a distinct time point. Only intact DNA from living cells is 
trapped in these filters, whereas small DNA fragments pass through. The more cells 
are killed, the less is the radioactivity on the filters. Thus, the radioactivity that is 
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measured corresponds to intact DNA and reflects the number of living targets that 
remain in each well.  
Labeling of target cells 
P815 cells in logarithmic growth phase were used as target cells. 3 x 105 cells were 
seeded in 1 ml IMDM medium compl. per well of a 12-well-plate. After addition of  
5 µCi [3H]thymidine per well, the cells were incubated for 4-6 h at 37°C in a humified 
atmosphere to allow incorporation of radioactivity. Finally, the target cells were 
washed two times with medium to remove excess of radioactivity and resuspended in 
an appropriate volume. 
Practical performance 
This cytotoxic T cell assay was performed directly (ex vivo) with spleen cells in 96-
well-plates with 104 labeled target cells in a total volume of 200 µl per well. Isolated 
spleen cells from immunized mice were used as effector cells in concentrations 
ranging from 105 to 106 cells/well to test different effector-to-target (E:T) ratios. After 
addition of 1 µg/ml antigenic peptide to the cell mix, the target cells were incubated 
with effector cells at different ratios for 4 h. Cells were either immediately harvested 
or stored at -20°C until they were analyzed. For this, cells were transferred to 
fiberglass filters by vacuum aspiration using a cell harvester. The fiberglass filters 
were dried and shrink-wrapped after addition of liquid scintillation fluid to count them 
in a ß-scintillation counter. As control, target cells alone or target and effector cells 
without specific antigen or with foreign antigen were used. 
[3H]thymidine TRA 310  : Amersham, Braunschweig, Germany 
Cell harvester, 
fiberglass filter  : Inotech (Wallac, Turcu, Finland) 
Scintillation fluid  : Betaplate scint (Wallac, Turcu, Finland) 
Scintillation counter  : 1450 MicroBeta Trillux (Wallac, Turcu, Finland) 
3 Methods 73 
 
3.7 Infection of immunized mice with L. monocytogenes 
Six to nine mice per group were challenged with 5 x 104 L. monocytogenes EGDe  
(10 x LD50 for BALB/c mice) i.v. into the tail vein and observed during two weeks for 
survival. Practically, Listeria were incubated overnight at 180 rpm and 37°C in BHI 
broth. Next morning the culture was diluted 1:10 in fresh BHI broth and grown for 
approximately 2 h. Concentration of bacteria was determined by measuring the 
OD600. Then the bacteria were washed in PBS and resuspended in PBS obtaining  
5 x 105 Listeria per ml. Bacterial numbers were confirmed by plating serial dilutions of 
the suspension. 
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4 Results 
At present, oral DNA immunization with attenuated S. typhimurium aroA- elicits a 
strong cellular immune response, consisting of CD4+ and CD8+ T cells, already after 
a single administration. In contrast, stimulation of humoral and protective responses 
was shown to require several applications of the vaccine (Darji et. al., 1997, 2000). 
The current vaccine consists of S. typhimurium aroA- carrying the commercially 
available pUC backbone-based pCMVß that drives antigen expression by the strong 
virally derived CMV promoter. The data obtained so far suggested that the amount of 
antigen expressed by this vector system was not sufficient in vivo to confer complete 
protection after a single dose of recombinant Salmonella. Therefore, the aim of this 
thesis was the improvement of the properties of the expression plasmid. 
In the first approach, eukaryotic promoters should be selected that possibly allow 
higher antigen expression than the strong CMV promoter. The higher expression of 
antigen should improve cellular responses and especially the induction of antibodies, 
systemically and mucosally, as well as protective immunity. 
From this first set of experiments, it became obvious that plasmid stability is the 
major problem in the improvement of Salmonella-based oral DNA vaccines. 
Generally, recombinant plasmids carry antibiotic resistance markers to facilitate 
identification and to allow plasmid retention in vitro by appropriate selection pressure. 
In the absence of stabilizing antibiotics, plasmids currently in use are unstable in vitro 
and in vivo. Since plasmid retention in vivo is critical for efficient gene transfer and, in 
addition, the application of antibiotic selection markers in the immunized host are not 
indicated, strategies needed to be developed to retain the expression plasmid in 
Salmonella without exogenous selection. Obviously, the high copy number of the 
expression plasmid pCMVß and its derivatives presently used in our laboratory put a 
heavy strain on the physiology of the Salmonella and the plasmid is lost rapidly 
without the stabilizing antibiotic. Lowering the copy number should consequently 
reduce the metabolic burden and hence improve plasmid retention. 
The copy number of plasmid is usually regulated by the plasmids origin of replication 
(ori). Therefore, new low copy number expression plasmids were constructed 
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employing different ori’s to stabilize the plasmid within S. typhimurium aroA- in vitro 
and especially in vivo. 
4.1 Influence of different promoters on oral genetic immunization 
with S. typhimurium aroA- 
Since it was demonstrated before that IFNg down-regulates virally derived promoters, 
such as the strong CMV promoter (Qin et al., 1997), IFNg that is produced during 
clearance of the S. typhimurium aroA- strain by the host possibly interferes with the 
activity of the CMV promoter after oral immunization. Therefore, a new series of 
recombinant S. typhimurium aroA- strains carrying plasmids that contain strong 
promoters of housekeeping genes or genes active in APCs were tested for their 
ability to induce specific immune responses. The expression of antigen driven by 
these promoters should be independent of the influence of IFNg. In addition, the  
IRF-1 promoter was included in this series, since the IRF-1 promoter is activated by 
IFNg. Recombinant S. typhimurium aroA- carrying an pUC-based eukaryotic 
expression plasmid encoding ß-galactosidase as antigen under the control of the 
human elongation factor 1a promoter (pEF1ß), the ubiquitin promoter (pUbiß), the 
macrophage-specific human lysozyme promoter (phLPß), the DC-specific CD11c 
promoter (pDCAß) and the human interferon regulatory factor-1 gene promoter 
(pIRF-1ß) were compared with the original human cytomegalovirus promoter 
(pCMVß) for the induction of specific CD4+ and CD8+ T cells. All of these new 
expression plasmids transformed in S. typhimurium aroA- were already available at 
the beginning of this study and kindly provided by A.I. Garbe. 
From in vitro cultures, it became obvious that all of these expression plasmids were 
rapidly lost in the Salmonella carrier, although, the different plasmids were lost at 
various degrees. Whereas the pCMVß and pDCAß are maintained approximately up 
to 50% - 80% after an overnight culture in the presence of ampicillin, the other 
plasmids are nearly completely lost under these conditions (data not shown). 
Nevertheless, groups of BALB/c mice were orally immunized by feeding 1 x 108 
recombinant Salmonella with a pipette. 18 days later spleen cells were isolated and 
analyzed in the JAM-assay for cytolytic activity of antigen-specific CD8+ T cells 
(Figure 4.1). Apart from the plasmids containing the IRF-1 promoter and hLP 
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promoter, all constructs were similar to the original pCMVß plasmid and no one could 
induce stronger cytolytic activity of CD8+ T cells than the originally used plasmid 
(Figure 4.1). However, these results have to be interpreted with care, since the 
problem of plasmid stability (as discussed above) sheds some doubts on direct 
comparison of these constructs and might have influenced the induction of immune 
responses. Only if all plasmid construct would be stably maintained in the Salmonella 
carrier to the same extend, the influence of the different promoters on antigen 
expression and subsequently the induction of specific immune responses can be 
compared and evaluated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1: Specific cytolytic activity of isolated splenocytes from BALB/c mice 
(ex vivo). Mice were orally immunized with a single dose of S. typhimurium aroA- 
transformed with the original plasmid pCMVß or the new pUC-based expression 
plasmids pEF1aß, pDCAß, pUbiß, phLPß or pIRF-1ß containing different promoters. 
As negative control, mice received a single dose of Salmonella without plasmid 
(aroA-). Splenocytes were isolated 18 days post infection (p.i.) and tested with 
radiolabeled P815 cells for specific cytolytic activity. Different effector to target ratios 
(E:T) were analyzed after in vitro stimulation with ß-gal peptide for 4 h in the JAM-
assay. 
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4.2 S. typhimurium aroA--mediated oral DNA vaccination with 
stabilized expression plasmids 
To solve the stability problem encountered in the first set of experiments, a series of 
completely new expression plasmids was constructed that consist of exchangeable 
cassettes comprising origin of replication, selection marker and antigen coding 
region. After transformation of the Salmonella carrier with this series of plasmids, the 
influence of copy numbers on plasmid segregation in vitro and in vivo was examined. 
In addition, the ability of these transformants to induce cellular and humoral immune 
responses as well as their ability to confer protection against a challenge with a 
bacterial pathogen was compared with the original eukaryotic expression plasmid. 
Moreover, the influence of different antibiotic selection markers on the induction of 
immune responses were analyzed due to their different contents of immuno-
stimulatory CpG motifs. 
4.2.1 Construction of novel expression vectors 
First, the high copy number plasmid pCMVß carrying the lacZ gene under the control 
of the human CMV promotor was modified in a way that the resistance cassette and 
the origin of replication (ori) could be exchanged at will by the introduction of new 
unique cloning sites. Therefore, the whole part containing the ampicillin resistance 
gene and the ori was removed from pCMVß by digestion with EcoRI and SalI. Then 
the ampicillin resistance gene and the pUCori were newly derived by PCR with 
primers containing several unique restriction sites 5’- and 3’-prime of the gene. In a 
second PCR, both sequences were fused together and the fragment was completed 
with the expression part of pCMVß including the CMV promotor, the gene for ß-
galactosidase and the polyA site after ligation via EcoRI and SalI resulting in the high 
copy number plasmid pCMVßm1A (Fig. 4.2A, B). Subsequently, the low copy 
number replicon pMB1 and p15A as well as the very low copy number ori of pSC101 
were amplified including the same restriction sites as used for the pUCori of 
pCMVßm1A. The pUCori was then exchanged with these fragments giving 
pCMVßm2A, pCMVßm3A and pCMVßm4A, respectively (Fig. 4.3). Additionally, the 
tetracycline resistance gene was amplified by PCR and used to replace the ampicillin 
resistance gene in the particular plasmids. Thus, further resistance marker for 
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experimental analysis was generated and its influence on the stability of the 
expression plasmid could be investigated. The resulting plasmids were named e.g. 
pCMVßm2T, when the tetracycline resistance was introduced instead of ampicillin. 
Moreover, for protection studies, the hly gene coding for listeriolysin of L. 
monocytogenes was incorporated instead of lacZ as antigen into pCMVßm2A 
resulting in pCMVhlym2A. Figure 4.3 displays schematically the whole series of 
expression plasmids that were constructed, including the expected copy numbers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2A: Construction of pCMVßm1A: Primer-pairs for the amplification of AmpR 
(P1/P2) and the pUCori (P3/P4) are indicated in the plasmid-card of pCMVß by 
arrows. For later cloning of pCMVßm1A, the pCMVß-backbone containing the CMV 
promoter and the lacZ gene for ß-galactosidase expression was isolated by digestion 
with EcoRI and SalI. 
 
pCMVß
7164 bp
ß-Gal
SV40 polyA
SV40 SD/SA     .
P4
P3
P1
P2
CMV IE
pUCori
AmpR
Cla I (1781)
Eco RI (2)
Sal I (4513)
Sma I (833)
Xho I (641)
Not I (820)
Not I (4294)
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Fig. 4.2B: Construction of pCMVßm1A. The ampicillin resistance gene (AmpR) and 
the pUCori were amplified by PCR to introduce several restriction sites fused by 
overlaying extension PCR and were completed with the lacZ expression cassette  
(ß-galactosidase) from pCMVß resulting in pCMVßm1A. 
First step:
a) amplification of AmpR b) amplification of pUCori
AmpR
P1
EcoRI
P3
SpeI KpnI BglII
P4
SalI
pUCori
SpeI KpnI BglII
P2
Second step:
Fusion of AmpR and pUCori by overlaying extension PCR.
Third step:
Ligation of the fused AmpR-pUCori-fragment with the pCMVß-fragment containing
the CMV promoter and the gene for ß-galactosidase expression via EcoRI and 
SalI.
 
pCMVßm1A
6110 bp
CMV IE
pUCori
AmpR
ß-Galactosidase
Cla  I (1781)
Eco R I (2)
Pst  I (24)
Sal  I (4513)
Sma  I (833)
Kpn  I (5173)
Spe  I (5175)
Bgl  II (5163) Xho  I (641)
Not  I (820)
Not  I (4294)
Sac  II (820)
Sac  II (4300)
Xba  I (625)
Xba  I (4507)
BamH I (631)
BamH I (709)
BamH I (4303)
BamH I (4501)
SpeI KpnI BglII
EcoRI
SalIP1
P4
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Fig. 4.3: Overview of plasmid constructs generated in this study. 
 
 
 
4.2.2 Transformation of S. typhimurium aroA- 
All expression vectors were introduced in S. typhimurium aroA- by electro-
transformation. Successful transformation was proven by isolation of plasmid DNA 
from mini-plasmid preparation and analytical digestion of the isolated plasmid. Since 
the Salmonella have a high nuclease activity, the additional wash step 7 was 
performed according to the manufacturer’s protocol. All tested clones contained the 
appropriate vector (data not shown). One clone from each transformation was 
chosen to set up a stock culture and stored at -70°C. 
pCMVhlym2A ~ 15-20 hly Amp R pMB1ori 
copies/ bacteria 
~ 5 Tet R pSC101ori lacZ 
~ 10-12 Amp R p15Aori lacZ 
~ 5 Amp R pSC101ori lacZ 
~ 500-700 Amp R pUCori lacZ 
pCMVßm2A 
pCMVßm1A 
pCMVßm3A 
pCMVßm4A 
pCMVßm2T 
pCMVßm3T 
pCMVßm4T 
~ 15-20 
~ 10-12 Tet R lacZ 
lacZ Tet R pMB1ori 
p15Aori 
~ 15-20 Amp R pMB1ori lacZ 
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4.2.3 Determination of plasmid copy number 
To examine the number of plasmids, which are present in one bacterium, strains of 
E. coli and S. typhimurium aroA- carrying either the high copy number plasmid 
pCMVß, the low copy number plasmids pCMVßm2A and pCMVßm3A or the very low 
copy number vector pCMVßm4A were grown overnight at 37°C until OD600 of ~0.8 
was reached. Plasmid DNA was extracted from 3 ml of the overnight culture by mini-
plasmid preparation. The cfu/ml were determined by plating on LB-agar plates 
containing antibiotics. To calculate the copy number, the amount of DNA solution 
was standardized to 5 x 108 bacteria (in the case of pCMVß 5 x 107 bacteria). The 
plasmids were digested with NotI and ClaI to obtain two fragments (2513 bp and 961 
bp) of the ß-galactosidase gene, which are identical in each construct. Then, the 
concentration of DNA was estimated by optical comparison with marker DNA after 
agarose-gel-electrophoresis (Fig. 4.4) and the copy number (see table 4.1) was 
calculated as follows: 
 
 
 
1. Estimation of DNA concentration by optical comparison with marker DNA using 
the formula: 
  
1 pmol of 1000 basepairs (bp) DNA = 0.66 µg 
  
2. Calculation of the number of molecules present in a single bacterium using the 
formula: 
  
1 µg of 1000 bp DNA = 1.52 pmol = 9.1* 1011 molecules 
  
          DNA concentration [pmol] * 9.1* 1011 molecules 
                                           1.52 pmol 
 
                        number of molecules/sample 
                         number of bacteria/sample 
 
 
= number of molecules/sample 
= copies/bacterium 
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Fig. 4.4: Determination of plasmid copy number. Lane 1 and 6: marker DNA; lane 
2: pCMVß; lane 3: pCMVßm2A; lane 4: pCMVßm3A; lane 5: pCMVßm4A. 
 
 
 
Table 4.1: Calculation of plasmid copy number. 
 
Plasmid Host strain copy number/bacteria 
pCMVß E. coli DH5a   ~ 650 
pCMVßm2A E. coli TOP 10     ~ 13 
pCMVßm3A E. coli TOP 10       ~ 8 
pCMVßm4A E. coli TOP 10       ~ 4 
pCMVß S. typhimurium aroA-  ~ 1120 
pCMVßm2A S. typhimurium aroA-     ~ 24 
pCMVßm3A S. typhimurium aroA-     ~ 14 
pCMVßm4A S. typhimurium aroA-      ~ 4 
S. typhimurium
E. coli
1       2        3       4        5       6 
E. coli 
S. typhimurium 
  ß-gal fragment 2513 bp 
 
 
  ß-gal fragment   961 bp 
  ß-gal fragment 2513 bp 
 
 
  ß-gal fragment   961 bp 
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4.2.4  S. typhimurium-mediated transfection of an established cell line 
Since gene-transfer in vitro with the original pCMVß plasmid was only shown 
efficiently in primary macrophages (Darji et al., 1997), but not in cell lines, it was 
investigated whether the increased plasmid stability in Salmonella could enhance the 
efficiency of gene-transfer. Hence, to compare the various new recombinant 
Salmonella strains in their ability to invade mammalian host cells and to mediate 
gene-transfer in vitro, the established HEp-2 cell line was infected.  
Infection of HEp-2 cells with the various recombinant Salmonella described above 
was carried out with an MOI (multiplicity of infection) of 200:1, 100:1 and 50:1 in a 
total volume of 200 µl. The MOI was confirmed by plating serial dilutions of the 
bacterial suspension on LB-agar plates. Cultures were centrifuged to enhance 
infection and incubated for 2 h at 37°C. Afterwards, extracellular bacteria were killed 
by addition of gentamicin to the cell culture. Salmonella-mediated gene transfer was 
assessed by X-gal staining of ß-galactosidase expressing cells 24 h post infection. 
Successful transfer of DNA was detected by cytoplasmatic staining of HEp-2 cells by 
light microscopy (Fig 4.5). Since the CMV promoter in Salmonella shows residual 
expression of ß-galactosidase, gene transfer has taken place only in cells that exhibit 
a homogenous X-gal staining of the cytoplasm, as shown in figure 4.5E. 
Surprisingly infection of HEp-2 cells with Salmonella carrying pCMVß resulted in high 
numbers of transfectants, while recombinant Salmonella harboring low copy number 
plasmids show only few ß-gal expressing cells. This was unexpected from results 
obtained in our lab (Darji et al., 1997) and by others (Grillot-Courvalin et al., 1999). 
However, only freshly thawed HEp-2 cells showed this phenomenon that was lost 
after several passages in culture. For reasons of time, it was not possible to further 
investigate this phenomenon. 
 
4 Results 84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5: Expression of ß-galactosidase in HEp-2 cells after transfection by  
S. typhimurium aroA- (S. t.). HEp-2 cells were infected at an MOI of 200:1 for 2 h 
with S. t. carrying either the expression plasmid pCMVß (A, E), pCMVßm2A (B), 
pCMVßm3A (C), pCMVßm4A (D), pCMVßm2T (F) or pCMVßm3T (G). 24 h p.i. cells 
were fixed and incubated with the indicator substrate X-gal. Expression of ß-galacto-
sidase activity was screened by light microscopy. Homogeneous staining of the 
whole cell is shown at a higher magnification after transfer of pCMVß from S. t. (E). 
E 
A 
B 
C 
D 
F 
G 
 
arrows indicate ß-gal 
expressing cells 
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4.3 Plasmid stability  
4.3.1 Growth curve 
First of all, it was important to know how the new expression plasmids influence the 
growth behavior of Salmonella typhimurium aroA- in vitro. The different copy number 
of plasmids present in the bacterium as well as plasmid size should represent a 
varying burden to Salmonella and might differentially interfere with their metabolism 
and viability. To test this, LB-broth containing the appropriate antibiotic was 
inoculated with a small amount of the transformants from the cryo-stock and 
incubated at 37°C and 180 rpm. At different time points, the optical density (OD600) 
was measured and the cfu/ml were determined by plating serial dilutions (Fig. 4.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6: Growth curve of S. typhimurium aroA- transformed with different 
eukaryotic expression plasmids encoding ß-galactosidase. 
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As shown in figure 4.6 all plasmid-bearing Salmonella have a similar growth rate in 
the presence of the corresponding antibiotic regardless whether they carry a high or 
low copy number vector. Furthermore, the number of viable bacteria during growth 
was examined by plating serial dilution on LB-agar containing appropriate antibiotics 
(Fig. 4.7). Thus, under aerobic conditions the various plasmids obviously do not 
interfere with viability and growth. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7: Determination of colony forming units of recombinant Salmonella in 
vitro. At different time points during growth of Salmonella harboring the original high 
copy number plasmid pCMVß or the newly derived low copy number eukaryotic 
expression plasmids, aliquots of the bacterial suspension were plated in serial 
dilutions on LB-agar plates containing the appropriate antibiotics. The cfu/ml were 
enumerated and plotted against the corresponding optical density (OD). 
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4.3.2 Plasmid stability in vitro 
From the growth curve in the presence of antibiotics and determination of cfu in the 
bacterial culture no obvious differences were observed. However, it was more 
important for this study to investigate the plasmid stability in vitro of S. typhimurium 
aroA- transformants under anaerobic conditions as used for vaccination experiments. 
Therefore, the recombinant Salmonella typhimurium aroA- were grown in LB-broth 
with or without antibiotic selection for several cycles of overnight cultures to analyze  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8: Experimental schedule to test plasmid stability of Salmonella 
transformants in vitro. In each cycle, bacteria were grown in LB-broth with and 
without antibiotics under anaerobic conditions at 50 rpm overnight up to an OD600 of 
~0.8. For the next cycle, bacterial suspensions were diluted 1:1000 in fresh broth. 
From each cycle, serial dilutions were plated on LB-agar with and without selective 
antibiotics and bacterial colonies were counted to calculate plasmid stability. 
serial dilutions
1:1000 1:1000 1:10001:1000
1. cycle 2. cycle 5. cycle4. cycle3. cycle
ri l dil ti ns
0 0 00
+antibiotics/
-antibiotics
S. typhimurium aroA-
+ eukaryotic expression
plasmid
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Fig. 4.9: Plasmid stability in vitro. Recombinant Salmonella were grown in culture 
with and without the appropriate antibiotic. Plasmid stability was calculated by plating 
on LB-agar with and without antibiotics. 
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the effect of an antibiotic-free environment on plasmid segregation at each cycle. 
Serial dilutions were plated on LB-Agar or LB-Agar containing selective antibiotics. 
Colony forming units were enumerated and the percentage of plasmid stability was 
calculated. The procedure of this experiment is schematically depicted in Figure 4.8. 
Antibiotic resistance was taken as indicator for the presence of the expression 
plasmid. 
As shown in Fig. 4.9, the high copy number plasmid pCMVß is rapidly lost, when the 
selective antibiotic is omitted, whereas addition of ampicillin resulted in nearly 100% 
plasmid stability over time. In contrast, the low copy plasmids pCMVßm2A and 
pCMVßm3A as well as pCMVßm4A (Fig. 4.9) are stably maintained in the 
Salmonella even without any selective antibiotic. Furthermore, low copy plasmids 
carrying the tetracycline resistance gene instead of ampicillin were also stably 
retained in Salmonella (Fig. 4.9). This is a very important step for the use of such 
vaccines, as they can be easily handled for large-scale production in fermenters. 
 
4.3.3 Plasmid stability in vivo 
Most important for the improvement of these novel eukaryotic expression plasmids 
for Salmonella-mediated gene transfer was their stabilization in vivo, since this most 
likely represents the strongest influences on immune-inductivity. 
To test this, groups of mice received a single oral dose of 1-5 x 108 recombinant 
bacteria intragastrically (i.g.) and bacterial colonization of murine tissues and plasmid 
retention in vivo was investigated over 21 days. At different time points, the spleen, 
mesenteric lymph nodes, Peyer´s patches and liver were removed from immunized 
mice and bacterial colonization and plasmid stability was assessed by plating the 
homogenized tissues on LB-agar plates with and without antibiotics (Fig. 4.10). 
The enumeration of bacterial colonies revealed that all Salmonella strains, including 
S. typhimurium aroA- carrying pCMVß, were capable of colonizing Peyer´s patches, 
mesenteric lymphnodes, spleen and liver. Salmonella expanded exponentially until 
day 7 to 10 and their numbers decreased up to day 21. Mesenteric lymphnodes and 
spleen were colonized with similar kinetics as Peyer´s patches but with 10- to 100-
fold lower number, respectively. Colony forming units in liver were similar to spleen 
(Fig. 4.11). 
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Fig. 4.10: Illustration of the working schedule to test colonization of murine 
tissues and plasmid stability in vivo. At day 2, 7, 10, 14 and 21 after inoculation of 
1-5 x 108 recombinant Salmonella i.g., organs were removed and the cfu/organ were 
determined after plating serial dilutions. 
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Fig. 4.11: Colonization of plasmid-bearing S. typhimurium aroA- in murine 
tissues. Peyer´s patches (PP), mesenteric lymphnodes (LN), spleen (M) and liver (L) 
were removed on day 2, 7, 10, 14 and 21. Single cell suspensions were lysed and 
plated in serial dilutions on LB-agar with (closed symbols) or without (open symbols) 
100 µg/ml ampicillin to determine the cfu/organ.  
 
 
 
In contrast to the new strains with the low copy number plasmids, S. typhimurium 
carrying the high copy number plasmid pCMVß were detected at a three fold lower 
number in all tissues, although the mice had received the same number of bacteria 
(Tab. 4.2). This observation confirms that the high copy number expression vector 
pCMVß represents a high metabolic burden for Salmonella, consequently reducing 
their ability to colonize murine tissues. 
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Tab. 4.2: Bacterial recovery in Peyer´s patches after oral application of  
                   recombinant S. typhimurium strains. 
 
expression plasmid Cfu/mouse recovery1) 
pCMVß 4 x 108   3.02 x 106 
pCMVßm2A 4 x 108   8.62 x 106 
pCMVßm3A 4 x 108   7.82 x 106 
pCMVßm4A 4 x 108 14.13 x 106 
 
1) only data from day 7 (day 10 for pCMVß) p.i. are shown 
 
 
 
Subsequently, plasmid stability in vivo of the newly constructed expression vectors 
was calculated from these data and compared with the multicopy pCMVß. As 
demonstrated in figure 4.12, the lower number of copies stabilizes the plasmids 
carried within the Salmonella. As already mentioned, S. typhimurium aroA- carrying 
the low copy number vectors could be detected in the Peyer´s patches, mesenteric 
lymphnode and spleen as well as in the liver (Fig. 4.11). The plasmids pCMVßm2A, 
pCMVßm3A as well as pCMVßm4A were retained absolutely stable throughout the 
whole observation period of 21 days. In contrast, the pCMVß was obviously lost 
within the first two days, since no Salmonella carrying pCMVß could be detected at 
the first time point that was analyzed. Taken together, these results show that 
lowering the copy number in the eukaryotic expression plasmids resulted in an 
increase of plasmid stability in vitro as well as in vivo. 
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Fig. 4.12: Plasmid stability in vivo. Some of the values at day 2 diverge from 100% 
stability due to the extremely low numbers of cfu at this time points. These values 
most likely represent experimental errors rather than significant numbers of bacteria 
that do not carry the expression plasmid. 
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4.4 Immune responses elicited by oral immunization 
The lower plasmid burden, due to the lower copy numbers, solved the problem of 
stability of the recombinant S. typhimurium aroA-. However, it was questionable 
whether this results in sufficient antigen expression to trigger an immune response in 
all three specific arms of the immune system, namely CD8+ and CD4+ T cells as well 
as antibodies. Therefore, groups of BALB/c mice were vaccinated intragastrically with 
either a single or four doses of 1 x 108 S. typhimurium aroA- carrying the original 
pCMVß or one of the newly established expression plasmids in a total volume of  
100 µl sodiumbicarbonate buffer per mouse using a gavage needle. Control mice 
were treated the same way with S. typhimurium aroA- without any expression 
plasmid. At various time points after immunization, mice were sacrificed, blood was 
collected and lymphocytes were isolated from spleen and mesenteric lymphnodes for 
analysis of specific immune responses. The induction of cytotoxic T cells, helper T 
cells and antibodies were analyzed by IFNg-specific ELISPOT, proliferation assay 
and antigen specific ELISA, respectively. The general procedure of oral immunization 
for Salmonella-mediated gene transfer in mice and analysis of immune responses 
was illustrated in figure 4.13. 
 
4.4.1 CTL response 
To assess the response of CD8+ CTLs, lymphocytes from spleen and mesenteric 
lymphnodes of BALB/c mice were analyzed (Fig. 4.14). The isolated lymphocytes 
were restimulated in vitro for 5 days in IMDM medium containing 1µg/ml ß-gal 
peptide aa 877-885 at 37°C in a humified atmosphere. Cells were harvested by 
centrifugation, washed 5 times with PBS, resuspended in IMDM medium and the 
number of viable cells was determined. 1 x 105 cells per well of a 96-well-ELISPOT 
plate were then stimulated with the specific ß-gal peptide or the LLO peptide  
aa 91-99 as a negative control for another 18 h at 37°C. Afterwards, the cells were 
lysed and IFNg production was detected by binding of peroxidase-conjugated IFNg 
specific antibodies. The development of the color reaction was stopped after 30-60 
min and single spots were counted visually by a microscope. 
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Fig. 4.13: Scheme of Salmonella-mediated oral DNA vaccination and analysis of 
immune responses that are elicited. 
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All Salmonella strains carrying low copy number plasmids, independent of the 
antibiotic resistance marker, provoked already after a single immunization a strong 
and specific cytotoxic T cell activity. This response was stronger for all low copy 
plasmid-carrying strains compared to the strain carrying the high copy number 
plasmid pCMVß (Fig. 4.14A). Four immunizations enhanced the number of IFNg 
producing cells after administration of Salmonella carrying pCMVß significantly, while 
the response raised by Salmonella transformants with the different low copy number 
plasmids increased only slightly (Fig. 4.14B).The same results were obtained using 
low copy number constructs, where the tetracycline resistance gene was inserted 
instead of the ampicillin resistance gene (Fig. 4.14). 
4.4.2 Helper T cell response 
Spleen cells as well as lymphocytes from mesenteric lymphnodes of immunized 
mice, already tested for cytotoxic activity in ELISPOT, were additionally tested in a 
helper T cell assay for specific proliferation of CD4+ cells. As antigen, ß-galacto-
sidase protein was used for the restimulation of the specific response, whereas LLO 
protein served as negative control (data not shown). The proteins were taken at 
concentrations of 0.3, 1 and 3 µg/ml and 3 x 106 cells/well were stimulated in 200µl 
medium, containing the protein antigen for 24 h. Specific proliferation was 
investigated by incorporation of WST for 4 h and color reaction was measured at 
OD480. 
Similar to the IFNg response of CTLs, after only a single dose proliferation of CD4+ T 
cells from spleen as well as from lymphnode was much stronger after administration 
of Salmonella carrying the low copy number vectors compared to the high copy 
plasmid pCMVß (Fig. 4.15A). Multiple applications could just boost the helper T cell 
response in mice which received pCMVß-bearing Salmonella, but not or only weakly 
in the case of the low copy plasmids. Obviously, using the low copy number plasmid 
transformants, the maximum of the specific response is already obtained using a 
single administration. 
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Fig. 4.14: ELISPOT on IFNg-secreting CD8+ T cells. Groups of mice that received 
either a single (A) or four doses (B) of recombinant Salmonella were analyzed for the 
induction of antigen-specific CD8+ T cells by IFNg-secretion in vitro. 
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Fig. 4.15: Proliferation of antigen-specific CD4+ T cells in spleen. After single (A) 
or four applications (B), CD4+ T cells were analyzed for antigen-specific proliferation 
following in vitro stimulation with 3 µg/ml ß-gal peptide. 
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4.5 Antibody response 
The antibody response so far was the most problematic with the original system 
based on pCMVß. Therefore, it was interesting to see how strong the antibody 
response, raised by the new strains, appeared. The analysis of specific antibody 
responses by ELISA were performed on serum samples taken simultaneously from 
immunized mice sacrificed for the cellular assays either 144 days after a single or 37 
days after the fourth administration. Serum from mice immunized with S. typhimurium 
without plasmid was taken as negative control. High ß-galactosidase-specific 
antibody titers could be detected in serum of mice inoculated with only a single dose 
of recombinant Salmonella carrying the low copy number vectors, whereas pCMVß-
bearing Salmonella evoke only a moderate antibody response (Fig. 4.16A). Several 
applications of any of the recombinant Salmonella strains could not significantly 
boost the specific antibody titer against ß-galactosidase (Fig. 4.16B).  
Since pooled sera from mice that received recombinant Salmonella carrying either 
the high copy number plasmid pCMVß or the very low copy number vector 
pCMVßm4A showed variable antibody titers against ß-galactosidase, we analyzed 
sera from individual mice. Serum was collected from mice after a single 
administration of 1 x 108 recombinant Salmonella four and eight weeks post infection 
(p.i.). In this experiment, ELISA from both time points was carried out at different 
days and the titers from both experiments might not be absolutely comparable. 
However, it became clear that pCMVß-bearing Salmonella provoke low antibody 
titers in all individuals, whereas Salmonella transformed with pCMVßm4A elicit high 
antibody titers only in some of the mice at the early time point. But at the later time 
point, all of the mice appeared to respond by antibody production (Fig. 4.17). 
 
Taken together, comparative studies between the high copy number plasmid pCMVß 
and the different low copy number plasmids, carrying the pMB1 replicon, p15A or 
pSC101 ori on the pCMVß backbone, revealed a dramatic increase in plasmid 
stability in vitro and in vivo. Furthermore, the increased stability resulted in a stronger 
induction of antigen-specific CD4 and CD8 T cells as well as antibody responses 
already after a single application. Moreover, antibody responses that are induced by  
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Fig. 4.16: Analysis of the antibody response. Serum samples of mice orally 
immunized either once (A) or four times (B) with recombinant Salmonella were 
examined for antigen-specific antibody titers against ß-galactosidase in ELISA. 
Serum samples were taken 144 days after a single and 37 days after the fourth 
administration. 
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the new recombinant Salmonella strains were remarkably long-lived, since high titers 
of ß-galactosidase-specific antibody titers could be detected still five month after a 
single oral dose. Such a strong and long-lived antibody response was never 
observed by the original system (Darji et al., 1997, 2000). This suggests that 
expression of low amounts of antigen after gene-transfer from Salmonella harboring 
low copy number vectors during a long period of time could prime stronger immune 
responses than do high amounts of antigen from multicopy plasmids present for a 
short time only.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.17: Analysis of antibody response from individual mice. Serum samples 
from individual mice were analyzed for ß-galactosidase-specific antibodies after 4 (A) 
and 8 (B) weeks p.i. with a single dose of recombinant Salmonella. 
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4.6 Transformation of S. typhimurium aroA- with two compatible 
oris 
For the construction of the low copy number plasmids, on the one hand, the pMB1 
replicon derived from ColE1 and, on the other hand, the ori from p15A was used. 
Since these both origins of replication should be compatible in the same bacterium, 
such a system could prove extremely useful for the co-delivery of antigen and 
modulating molecules. To show the feasibility of such an approach, S. typhimurium 
aroA- was transformed with the expression plasmid pCMVßm3T together with 
pCMVhlym2A. Both plasmids could be distinguished in the bacterial cultures due to 
the different antibiotic resistance marker they carry. Consequently, Salmonella 
carrying these two compatible plasmids should be resistant against ampicillin and 
tetracycline, thus, facilitating the evaluation of plasmid stability in vitro and in vivo. 
Furthermore, the hly gene coding for listeriolysin of L. monocytogenes was 
incorporated into pCMVßm2A replacing ß-galactosidase as antigen. Using this 
second antigen, the induction of immune responses against either of these antigens 
could be examined after Salmonella-mediated gene transfer. In addition, the 
generation of protective immunity against a lethal challenge with L. monocytogenes 
by the double-transformed Salmonella could be analyzed and compared to the 
strains carrying single low and high copy number vectors encoding listeriolysin. 
Stability in vitro and in vivo 
First, the plasmid stability of Salmonella carrying the two compatible, low copy 
number vectors pCMVßm3T and pCMVhlym2A was investigated in vitro. In the 
presence of selecting antibiotics, the double-transformed Salmonella retain both 
plasmids at 60% after five passages. Without selection pressure none of the 
Salmonella containing both plasmids could be detected after the second cycle (Fig. 
4.18). Plating the Salmonella on LB-agar plates containing either tetracycline or 
ampicillin revealed that only one of the plasmids was lost and the other was retained. 
No plasmid preference was observed, as depending on the particular experiment one 
or the other plasmid was lost (data not shown). 
These recombinant Salmonella were also limited in their ability to colonize murine 
tissues, since 10- to 100-fold lower number could be detected in the organs 
compared to pCMVß-carrying Salmonella. In addition, only Salmonella carrying one 
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vector, but no double-transformed Salmonella could be recovered from the tissues. 
Again no preference for a particular plasmid was observed, since in one experiment 
only pCMVhlym2A was recovered, while in the second experiment only pCMVßm3T 
was retained (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.18: Plasmid stability in vitro of S. typhimurium aroA- carrying two 
compatible plasmids. S. typhimurium was transformed with the low copy vector 
pCMVßm3T encoding the ß-galactosidase as well as with pCMVhlym2A expressing 
LLO as antigen. Carrying the tetracycline resistance or ampicillin resistance gene, 
respectively, facilitates selection and assessment of plasmid stability.  
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Induction of immune responses 
Although Salmonella carrying two low copy number plasmids with compatible origins 
of replication were relatively unstable in vitro and reduced in their ability to colonize 
murine tissues, we nevertheless investigated whether this Salmonella strain could 
induce immune responses against both antigens encoded by these compatible 
plasmids.  
Groups of mice received either one or four doses of recombinant Salmonella as 
described above. The ability of the double-transformed Salmonella to provoke 
immune responses was compared to Salmonella carrying the high copy plasmid 
pCMVhly, the low copy number pCMVhlym2A or pCMVßm3T. The mixture of 
Salmonella carrying either pCMVhlym2A or pCMVßm3T at a ratio of 1:1 was 
included for the single administration and S. typhimurium aroA- without plasmid 
served as negative control. 
Helper T cell response 
To assess the CD4+ helper T cell response, isolated lymphocytes from spleen (Fig. 
4.19) and mesenteric lymphnodes (data not shown) were recovered 36 days after a 
single or the fourth administration of the recombinant bacteria and restimulated either 
with ß-galactosidase or LLO protein as specific antigen (Fig. 4.19A; B). The 
alternative protein that was not encoded by the immunizing plasmid was used as 
unspecific control antigen. 
Salmonella carrying the compatible plasmids could induce a strong and specific 
immune response against both antigens after a single administration. Besides, the 
strength of cell proliferation is comparable to both low copy plasmids given as single 
construct (Fig. 4.19A). Furthermore, the double-transformed bacteria elicit a CD4+ T 
cell response as strong as a mixture of Salmonella carrying either pCMVhlym2A or 
pCMVßm3T. 
Analysis of the CD8+ T cell response revealed that approximately the same number 
of specific IFNg-producing cells was induced by immunization with Salmonella 
carrying pCMVhlym3T, pCMVßm2A, both plasmids together in the same bacteria, or 
a mixture of Salmonella carrying either of these plasmids (Fig. 14.19C). Multiple 
applications hardly increased the specific cellular immune responses as observed 
before (Fig. 4.19B, D). 
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Fig. 4.19: Induction of immune responses in spleen after oral administration of 
S. typhimurium aroA- carrying either single or two compatible plasmids. Mice 
were immunized with Salmonella transformed with either the high (pCMVhly) or low 
copy number plasmid (pCMVhlym2A) encoding listeriolysin (LLO), the low copy 
number plasmid pCMVßm3T coding for ß-galactosidase or the plasmid pCMVhlym2A 
together with pCMVßm3T (pCMVhlym2A/pCMVßm3T). As negative control, mice 
received Salmonella without plasmid (aroA). Immune responses were analyzed 144 
days after application of a single (A, C) or 37 days after the fourth (B, D) dose of 
recombinant Salmonella. Antigen specific proliferation of CD4+ T cells in response to 
ß-galactosidase or listeriolysin protein was measured in a helper T cell assay and 
quantitated spectrophotometrically at OD480 (A, B). Induction of antigen-specificCD8+ 
T cells was assessed by determining the number of IFNg-secreting cells after in vitro 
stimulation with ß-galactosidase peptide aa 877-885 or LLO peptide aa 91-99, 
respectively (C, D). In addition, mice were fed orally with a mix of Salmonella 
harboring either pCMVhlym2A or pCMVßm3T (pCMVhlym2A + pCMVßm3T) and 
immune responses were analysed 36 days after a single administration (A, C). 
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Fig. 4.20: Antibody response against ß-galactosidase in BALB/c mice after 
immunization with S. typhimurium aroA- carrying either single or two 
compatible plasmids. Mice received either a single (A) or four (B) doses of 1 x 108 
recombinant Salmonella as described above. Salmonella without plasmid served as 
negative control (aroA). Serum samples were assessed for ß-gal-specific antibody 
titers in ELISA in a dilution of 1:1000.  
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Antibody response 
Serum samples of mice immunized once or four times with Salmonella carrying the 
low copy vectors pCMVhlym2A and pCMVßm3T together in the same bacterium 
were investigated for specific antibodies against listeriolysin and ß-galactosidase, re-
spectively. In comparison, Salmonella harboring either pCMVßm3T or pCMVhlym2A 
or a mixture of Salmonella strains carrying pCMVßm3T and pCMVhlym2A (data not 
shown), the double-transformed bacteria stimulated a ß-gal-specific antibody 
response of similar strength. This antibody response could not be increased by 
multiple administrations of Salmonella, as already observed for T cells (Fig. 4.20). 
The ELISA for specific LLO antibodies, raised by the strains transformed with 
pCMVhlym2A or pCMVhly, revealed no clear results, indicating low titers. 
 
In summary, immunization with Salmonella carrying two different antigens encoded 
by low copy number vectors with compatible origins of replication, elicits strong and 
specific immune responses against both, LLO and ß-gal. Although these double-
transformed Salmonella are not as stable as S. typhimurium carrying either of the low 
copy plasmids, the induction of CD4+ and CD8+ T cells as well as antibodies is 
comparable and requires only a single administration. In contrast, Salmonella 
harboring the high copy number plasmid that appear to loose their plasmid with a 
similar kinetic as the double transformed bacteria could stimulate such high 
responses only when multiple doses were applied. 
 
4.7 Infection of immunized mice with L. monocytogenes 
To test whether vaccination with Salmonella carrying one low copy number vector or 
two compatible plasmids would result in an immune response that could confer 
protection against a lethal infection with a pathogenic microorganism, mice were 
intragastrically inoculated with the recombinant Salmonella as above and challenged 
with a dose of L. monocytogenes corresponding to 10 x LD50. As a positive control, 
mice were immunized with a sublethal dose of 1 x 103 L. monocytogenes 10 days 
prior to challenge and naïve BALB/c mice served as a negative control. Survival of 
mice was observed for two weeks post infection. 
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Fig. 4.21: Protection against challenge with a lethal dose of L. monocytogenes 
after oral immunization with various recombinant S. typhimurium aroA-. BALB/c 
mice obtained either single (A) or four doses (B) of Salmonella carrying the high copy 
(pCMVhly) or the low copy vector (pCMVhlym2A) expressing LLO, or the low copy 
vector pCMVhlym2A together with pCMVßm3T (pCMVhlym2A/pCMVßm3T). Naïve 
mice (uninfected) and mice that received one or four doses of Salmonella without 
plasmid (aroA) served as negative control. As positive control, a group of mice was 
immunized with a sublethal dose of 1 x 103 Listeria (L.m.) 10 days prior to infection. 
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Mice that had received multiple administrations of transformants harboring a LLO 
expression plasmid were completely protected, independent of the copy number or a 
second compatible expression vector (Fig. 4.21B). In contrast, a single administration 
of such transformants could only partially protect infected BALB/c mice against  
L. monocytogenes (Fig. 4.21A). 
 
 
 
All together, lowering the copy number in eukaryotic expression plasmids showed a 
remarkable increase in plasmid stability in vitro as well as in vivo and subsequently 
resulted in an enhanced induction of all specific arms of the immune system. 
However, in protection studies using listeriolysin as antigen BALB/c mice were only 
partial protected against a lethal dose of L. monocytogenes after a single 
administration, independent whether Salmonella were carrying a high or low copy 
number vector or two compatible low copy plasmids. Only after multiple applications 
of LLO plasmid-carrying Salmonella, all mice were protected. These observations 
lead to the conclusion that, despite a stronger induction of immune responses by 
Salmonella transferring low copy number vectors, the generation of memory T cells is 
not sufficient to protect mice against a lethal dose of L. monocytogenes after only a 
single administration. On the other hand, the new strains of Salmonella induced a 
long-lasting antibody response. Thus, the improved stability can be considered as a 
step forward in the generation of improved Salmonella-based oral DNA vaccines. 
Employing plasmids with compatible origins of replication as described here will allow 
further improvements that should finally result in protective immunity after only a 
single administration. 
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5 Discussion 
Vaccination is the most cost-effective strategy to prevent infectious disease. Despite 
the introduction of several successful vaccines until today, some major infectious 
threats remained unchanged and new threats like HIV or drug resistant 
Mycobacterium tuberculosis newly occurred. Thus, there is a growing need to design 
improved or completely new vaccines. Most vaccines that are currently available are 
mainly based on the induction of long-lived antibody responses. However, some 
intracellular bacteria, parasites and viruses also might need T cell-mediated cellular 
immune responses to be cleared. 
In this respect, oral application of DNA vaccines using Salmonella as delivery system 
represents a highly versatile possibility to induce antigen-specific cytotoxic and 
helper T cell responses, as well as antibodies. This kind of vaccination was far 
superior to immunization with Salmonella expressing the antigen as heterologous 
protein with regard to immune and memory induction. In addition, mice were partially 
protected against L. monocytogenes when immunized once with the appropriate oral 
DNA vaccine. Despite the strong induction of cellular immune responses, induction of 
antibodies is only possible under optimal conditions and mainly systemic instead of 
mucosal as might have been expected for a mucosally applied vaccine (Darji et al., 
2000). Therefore, improvement of Salmonella–mediated gene transfer is required to 
render the system suitable for general application. 
It has been reported that strong, constitutive, viral promoters do not cause long-term 
transgene expression in vivo (Scharfmann et al., 1994; Challita and Kohn, 1994; 
Rettinger et al., 1994), since cytokines like IFNg and TNFa that are induced during 
the immune response inhibit transgene expression from viral promoters (Qin et al., 
1997). This suggested that the CMV promoter might be not the most appropriate one 
for Salmonella-mediated oral DNA vaccination. 
For that reason, Salmonella-mediated gene transfer should be improved in this thesis 
by comparing different eukaryotic promoters with the presently used viral CMV 
promoter. On the one hand, promoters of housekeeping genes like the elongation 
factor 1a promoter or ubiquitin promoter and, on the other hand,   tissue specific 
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promoters like the macrophage specific human lysozyme promoter or the dendritic 
cell specific CD11c promoter were employed. Such promoters should not be down-
regulated by IFNg. In addition, the promoter of the interferon regulatory factor-1 was 
tested, since this promoter is activated by IFNg.  
Analysis of CTL responses after immunization with recombinant Salmonella revealed 
that the EF1a, CD11c and ubiquitin promoter were as good as the CMV promoter in 
the induction of specific CD8+ T cells. In contrast, stimulation of cytotoxic T cells was 
extremely low when antigen expression was driven by the hLP or the IRF-1 promoter. 
Since the hLP promoter is active in macrophages, the weak CD8+ response that was 
induced after immunization could be explained by the presence of few macrophages 
in the Peyer´s patches. Thus, antigen expression driven by the hLP promoter would 
have been not sufficient to stimulate a strong CD8+ response. Another possibility for 
the low response could be that the promoter was weak or not functional at all, as its 
functionality could not be tested in vitro beforehand. Antigen expression driven by the 
CD11c promoter, surprisingly, induced a strong CTL response. Possibly, antigen 
expression in the DCs themselves was leading to efficient presentation of antigen 
and induction of T cells, supporting the important role of DCs as antigen presenting 
cells after Salmonella-mediated gene transfer. In contrast, the immune response 
provoked by antigen expression from the IRF-1 promoter was unexpectedly low. 
Either this promoter is very weak, resulting in too low amounts of antigen, or the 
promoter was not activated by IFNg. Since IFNg-secretion by cells of the host defense 
is induced at rather late time points and all high copy number derivatives of pCMVß 
are lost rapidly in vivo this cytokine might not activate the promoter in time. 
This hypothesis would fit well with the observation that constructs containing the 
CMV promoter elicit strong immune responses, although it was reported that IFNg 
down-regulates the activity of the CMV promoter. Consequently, IFNg production is 
encountered at a time when the expression plasmid might already be lost. Hence, 
IFNg could not inhibit the promoter activity of CMV anymore. 
However, such general comparisons between the promoters should be taken cum 
grano salis, since the experiments have been hampered by severe stability problems 
of the plasmids in the Salmonella carrier in vitro. Thus, it became clear that the 
problem of plasmid stability had to be solved first, before definite conclusions on the 
optimal promoter could be considered for further improvements of such vaccines. 
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Accordingly, the main part of this study includes the enhancement of plasmid stability 
on the basis of different origins of replication to lower the number of copies within the 
bacterium. To construct different eukaryotic expression plasmids, the conventionally 
used vector pCMVß was reconstructed in the way that single cassettes for the ori, 
the resistance gene, the promoter and the antigen coding sequence could be easily 
exchanged when required. This has the advantage that additional ori´s (e.g. F-factor) 
can be inserted without further manipulation of the plasmid backbone and analyzed 
comparatively for properties like stability in Salmonella as well as their co-existence 
with other compatible plasmids. In the same way, the promoter and the antigen can 
be exchanged and investigated for their potential to induce specific immune 
responses. Finally, antibiotic selection markers could be replaced against different 
resistance markers, first of all for analysis purposes. Similarly, the antibiotic 
resistance could be replaced by a balanced suicide system at later stages i.e. a gene 
that complements a monogenic defect in the bacterial carrier (e.g. asd/Dasd). 
After transformation of S. typhimurium with the eukaryotic expression plasmids, 
plasmid stability in vitro and in vivo, as well as immune responses stimulated after 
oral immunization, were analyzed. Compared to the high copy number vector pCMVß 
that bears the pUCori, the low copy number vectors pCMVßm2A, pCMVßm3A and 
pCMVßm4A containing the pMB1 replicon, p15Aori or pSC101ori, respectively, were 
all stably retained in the Salmonella strain in vitro during several passages in LB-
broth without any selective pressure. The successful stabilization of plasmids in 
Salmonella without the need of stabilizing antibiotics is especially important for large-
scale fermentation. It will simplify the handling and should reduce the costs of 
production of the vaccine. 
In addition, Salmonella harboring low copy number expression plasmids could be 
detected for three weeks in mouse tissues, whereas no Salmonella carrying the 
multicopy plasmid pCMVß could be detected. The increased plasmid stability 
consequently resulted in a stronger induction of CD4+ and CD8+ T cells as well as 
antibody responses already after a single oral administration of 1 x 108 recombinant 
S. typhimurium aroA-. Furthermore, the strength of immune responses elicited by 
these low copy number vectors was independent of whether they were carrying the 
ampicillin or tetracycline resistance cassette. 
There exist several reports about immunostimulatory CpG motifs that can enhance 
the immune response after addition into plasmid DNA. But this property might be only 
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valuable by using naked plasmid DNA. At least, the exchange of ampicillin, which 
contains two known CpG motifs, against tetracycline comprising only one known 
CpG motif in the plasmid backbone had no influence on the induction of immune 
responses after Salmonella-mediated gene transfer. This phenomenon is very likely 
due to the presence of high amounts of bacterial DNA that overwhelm the influence 
of minor differences of immuno-stimulatory CpG contents in the plasmid DNA of the 
eukaryotic expression plasmid by this kind of vaccination. 
The lower number of copies present in the Salmonella carrier, due to the different 
origins of replication tested in this study, is responsible for the stable maintenance of 
the eukaryotic expression plasmids, but also reduces the level of antigen expression. 
Nevertheless, as shown in this thesis, lower antigen expression over a long period of 
time by the low copy number vectors pCMVßm2A and pCMVßm3A and their 
corresponding tetracycline derivatives induce much stronger immune responses after 
a single application compared to high levels of antigen-expression for a short time by 
the multicopy plasmid pCMVß. In comparison to the low copy number vectors 
pCMVßm2A and pCMVßm3A, the induction of immune responses by the very low 
copy number plasmid pCMVßm4A was weaker and resembled more the high copy 
number vector pCMVß. In contrast to the original pCMVß plasmid, all low copy 
number plasmids, including pCMVßm4A, provoked a strong long-lasting antibody 
response. This suggests that, on the one hand, the stability is more important than 
the copy number for efficient antigen expression. On the other hand, the copy 
number should be as high as possible, since the very low copy number plasmid is 
stably retained in Salmonella, but antigen expression due to the very low number of 
copies was not sufficient to induce exceptionally strong immune responses. 
Therefore, strategies that enhance antigen expression in vivo by these stable low 
copy plasmids have to be considered. On this score, improvement of DNA vaccine 
vectors to create in vivo amplification systems of antigen expression, such as the 
alphaviral replicon, might be advantageous. Another approach could make use of a 
system for the inducible amplification of copy numbers as it is already employed in 
vitro with the pETcoco system (Novagen, Madison, WI). Moreover, the different 
promoters that were already tested in pUCori-based plasmids should be re-analyzed 
in the stable low copy plasmids. Such experiments might reveal differences amongst 
these promoters that were not observable with the unstable high copy number 
expression plasmids. 
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Interestingly, induction of long-lasting antibody responses was achieved by the newly 
but not by the original expression vector system. This might confer protection in 
infection models where long-lived antibody responses are required for host defense 
as in the case of extracellular bacteria or viruses. However, despite of this, single 
administration of the oral Salmonella-based DNA vaccine only partially protected 
mice against L. monocytogenes using listeriolysin as antigen in challenge studies. 
Multiple applications resulted in complete protection against a lethal dose of  
L. monocytogenes. These findings lead to the conclusion that lowering the copy 
number certainly could enhance the induction of immune responses, but it is not 
sufficient to induce an adequate T cell memory for protection against an intracellular 
pathogen like L. monocytogenes.  
The explanation for incomplete protection via cell-mediated responses might be as 
follows: Upon primary infection, naïve T cells encounter antigens in the lymphoid 
tissues and subsequently expand clonally and differentiate into effector T cells. 
Effector T cells comprise CD4+ T cells of the Th1 or Th2 phenotype as well as CD8+ 
T cells known as cytotoxic T lymphocytes. After massive expansion, the majority of 
effector cells die and immunity contracts to memory levels, during which the number 
of memory T cells are stabilized and maintained for long periods of time. Thereby, 
the number of memory T cells is determined by the extent of expansion and cell-
death of initial effector cells (reviewed by Kaech et al., 2002). Application of 
Salmonella carrying low copy number expression plasmids obviously results in an 
increased recruitment or proliferation, since stronger T cell responses were 
observed. However, these improved vaccines seem not to interfere with the 
subsequent contraction phase. Therefore, the identification of molecules that 
interfere with cell-death might enhance T-cell memory and in turn, might provide 
better immunological memory after a single vaccination. 
So far, several cytokines and co-stimulatory molecules are known, which influence 
the quantity and quality of memory T cells. Cytokines, like type I IFNs and members 
of the IL-2 family (IL-2, IL-4, IL-7 and IL-15), were shown to reduce the rate of cell-
death in vitro and in some cases in vivo by directly inhibiting apoptosis and/or 
enhancing effector T cell proliferation (Zhang et al., 1998; Tan et al., 2001; Vella et 
al., 1998; Marrack et al., 1999; Sprent et al., 2000). Moreover, it was demonstrated 
that high levels of IL-4, IL-7 and IL-15 in vivo could increase the number of antigen-
specific CD4+ and CD8+ T cells and IL-15 could additionally enhance protective 
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responses (Vella et al., 1998; Yajima et al., 2002; Khan and Casciotti, 1999; Maeurer 
et al., 2000). 
Similarly, molecules of the TNF receptor family and their ligands like CD27 and 
CD154 (CD40L) might also play an important role in the development of memory  
T cells. As example, experiments with CD154-deficient mice revealed that CD40-
CD154 interactions interfere with the contraction phase and prevent death of effector 
CD8+ T cells, consequently influencing the formation of memory T cells (Borrow et 
al., 1996; Whitmire and Ahmed, 2000). In addition, CD154 is essential for the 
induction of T cell-mediated protective immunity against viruses, parasites and 
tumors (Gurunathan et al., 1998; Sin at al., 2001; Xiang et al., 2001) by providing 
costimulatory activity on DCs via CD40-CD154 interactions. Co-administration of one 
or more of such molecules together with specific antigen might improve the 
Salmonella-mediated gene-transfer in such a way that protective immunity is 
achieved already after a single oral administration. 
Moreover, co-delivery of different costimulatory molecules or cytokines that can 
modulate the immune responses into the desired direction might likewise confer 
better protection. For instance, co-expression of IL-4 or IFNg and IL-12 could bias T 
cells into a Th2 type or Th1 type response, respectively. Thereby, these cytokines 
might support appropriate effector functions and help to clear pathogens. 
Co-delivery of modulating molecules can be achieved by bi- or multicistronic 
expression using an IRES sequence. But encoding two or more genes on the same 
plasmid enlarges the plasmid size and thus might influence plasmid stability. In 
addition, gene-co-expression behind an IRES is often diminished and sometimes 
even not possible. In this respect, the use of plasmids with compatible ori´s in the 
same bacterium as described in this thesis could solve such problems. It was already 
shown in this study that two unrelated antigens encoded on compatible plasmids 
could generate strong CD4+ as well as CD8+ T cell responses against both antigens. 
Within the time frame of this thesis, it was not possible to definitely demonstrate, 
whether both antigens are expressed in the same target cell. This might be important 
in cases of immune modulation or where the homing of APCs should be influenced 
e.g. by the expression of chemokine receptors or integrins, which target APCs to gut 
associated mucosal tissues. Nevertheless, compatible plasmids should result in 
further improvements that finally lead to protective immunity upon a single application 
of Salmonella-based oral DNA vaccines.  
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In the same way, the selection of the Salmonella carrier (as already mentioned 
above) might have an impact on the outcome of protective immunity. Whereas  
S. typhimurium aroA- requires Th1 cells and IFNg for clearance, S. typhimurium of the 
PhoP- phenotype involves innate immune responses of macrophages (Van Cott, 
1998). Consequently, more systematic experiments will be required to find an optimal 
combination of features of the expression plasmid and the appropriate bacterial 
carrier. 
Taken together, it was demonstrated that lowering the copy number strongly increase 
plasmid stability in vitro and in vivo and consequently enhance specific immune 
responses after oral DNA vaccination with S. typhimurium aroA-. Complete protection 
against a lethal challenge with L. monocytogenes after application of the low copy 
number vectors as well as with the multicopy plasmid pCMVß was only possible after 
multiple vaccinations. This indicates that a single dose is not sufficient to recruit a 
strong immunological memory for cellular mediated responses as required for 
clearance of intracellular pathogens like L. monocytogenes. However, Salmonella 
bearing low copy number expression plasmids induce exceptionally long-lived 
specific antibodies that have been never observed before using the original high copy 
number plasmid pCMVß (Darji et al., 2000), after already a single administration. 
Hence, using the appropriate infectious model e.g. a virus model that need a strong 
antibody mediated response to resolve the infection, mice might be protected even 
after a single oral dose. 
Thus, we consider the improved stability as a first step towards a second generation 
of Salmonella-based oral DNA vaccines. The employment of plasmids with 
compatible origins, as described in this study, will allow further improvements that will 
confer protective immunity already after a single oral dose of recombinant Salmonella 
vaccines. More systematic analysis of this vaccination strategy will pave the way for 
the development of efficient vaccines that are general applicable to treat infectious 
diseases of bacteria, parasites and viruses as well as cancer and allergic diseases. 
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6 Summary 
Salmonella-mediated oral DNA vaccination has established itself as a very potent 
and versatile way of immunization. The use of commercially available multicopy 
expression vectors based on pUC origin of replication (ori) transferred by Salmonella 
typhimurium aroA- to mice has resulted in protective responses against pathogens 
and tumors. Nevertheless, the present combination of the Salmonella carrier and the 
antigen-expressing plasmid could induce strong antibody responses only under 
optimal conditions (Darji et al., 1997; 2000). In addition, to protect mice against a 
lethal dose of Listeria monocytogenes, several administrations of Salmonella carrying 
listeriolysin as antigen had to be applied. Therefore, an improved expression vector 
system should be developed. First, high copy number expression plasmids with 
different eukaryotic promoters were tested. No improvement over the original CMV 
promoter was observed. However, during these experiments, it was recognized that 
the general applicability of this system has been hampered by a severe instability of 
the expression plasmids.  
Thus, new low copy number expression plasmids were constructed using different 
ori’s to stabilize the plasmid. Comparative studies between the high copy number 
plasmid pCMVß and the different low copy number plasmids, carrying the pMB1, 
p15A or pSC101 ori on the pCMVß backbone, revealed a dramatic increase in 
plasmid stability in vitro as well as in vivo. Analyzing the immune responses against 
antigens encoded by these vectors indicated that the increased stability consequently 
resulted in a stronger induction of antigen specific CD4+ and CD8+ T cell as well as 
antibody responses, already after a single administration. In protection studies using 
listeriolysin as antigen, mice were only partial protected against a lethal dose of  
L. monocytogenes after a single administration, independent of whether Salmonella 
were carrying the high or the low copy number plasmids. After four immunizations, all 
mice were completely protected. However, in contrast to immunization with 
Salmonella bearing the high copy number plasmid, the newly established Salmonella 
harboring low copy number expression plasmids induce a long-lasting antibody 
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response. Thus, the improved stability of the vectors represents a first step towards a 
second generation of Salmonella-based oral DNA vaccines.  
Low copy number compatible ori’s allow transformation of Salmonella with two 
expression plasmids. Such Salmonella strain confers strong immunity to the different 
plasmid derived antigens, although the plasmids were as stable as single low copy 
vectors alone. Nevertheless, this strategy will allow further improvements e.g. by 
coadministration of plasmids encoding cytokines or costimulatory molecules. Such 
improvements will finally lead to the designated goal of establishing an oral DNA 
vaccine that yields a live long protective response already after a single 
administration. 
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7 Abbreviations 
aa  amino acid 
AmpR  ampicillin resistence marker 
APC  antigen presenting cell 
asd  aspartate-semialdehyddehydrogenase 
BHI  brain heart infusion 
bp  baisepairs 
CD  cluster of differentiation 
cfu  colony forming units 
CmR  chloramphenicol resistence gene 
CMV  cytomegalovirus 
CpG  Cytosine-phosphate-Guanosine 
CTB  cholera toxin subunit B 
CTL  cytotoxic T lymphocyte 
DC  dendritic cell 
DHB  2, 3-dihydroxybenzoate 
DNA  deoxyribonucleic acid 
DPT  Diphtheria Pertussis Toxoids 
E:T  effector-to-target ratio 
EDTA  ethylenediaminetetraacetate 
ELISA  enzyme-linked immunosorbent assay 
ELISPOT enzyme-linked immunospot assay 
F  Farad 
FAE  follicle-associated epithelium 
FCS  fetal calf serum 
g  gravitational acceleration 
GM-CSF granulocyte macrophage-colony stimulatory factor 
gp  glycoprotein 
HIV  Human Immunodeficiency Virus 
HLA  human leukocyte antigenes 
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HSV  human simian virus 
i.v.  intravenous 
IFN  Interferon 
Ig  immunoglobolin 
IL  Interleukin 
IMDM  Iscove's modified Dulbecco's modified Eagle's medium 
IRES  internal ribosomal entry site 
IRF  interferon regulatory factor 
ISCOM immune stimulatory complexes 
kanR  kanamycin resistance gene 
LACK  Leishmania homologue of receptors for activated C kinase 
LB  Luria Bertani 
LLO  listeriolysin O 
LN  lymphnode 
LTB  B-subunit of the heat-labile enterotoxin from E. coli 
M cell  microfold cell 
MALT  mucosa-associated lymphoid tissue 
MHC  major histocompatibility complex 
MOI  multiplicity of infection 
NK cell natural killer cell 
OD  optical density 
OPD  O-phenylendiamine 
ori  origin of replication 
p.i.  post infection 
pAB  p-aminobenzoid acid 
PBS  phosphate buffered saline 
PCR  polymearase chain reaction 
PEG  polyethylenglycol 
PP  Peyer´s patches 
PrV gD glycoprotein D gene of pseudorabies virus 
rpm  rounds per minute 
RT  room temperature 
spp.  subspecies 
TAE  tris-acetic acid-EDTA 
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TE   trypsin-EDTA 
TetR  tetracycline resistance gene 
Th cell T helper cell 
TLR  Toll-like receptor 
Tn  transposon 
TNF  tumor necrosis factor 
U  unit 
UV  ultraviolet 
V  Volt 
v/v  volume per volume 
w/v  weight per volume 
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